

List of expert advisory panel members and declarations of interest

Name	Job title and organisation	Type of interest	Description of interest	Relevant dates	Comments
Susan Bewley (Chair of main panel and therapeutic subpanel)	Professor Emeritus (honorary) in Obstetrics & Women's Health, King's College London	Non-financial professional and personal	Chair the charity Healthwatch-UK ('for science & integrity in medicine'), and a Trustee of Maternity Action. Neither relevant to the guideline	Ongoing	Declare and participate. Interest is non-specific
Susan Bewley (Chair of main panel and therapeutic subpanel)	Professor Emeritus (honorary) in Obstetrics & Women's Health, King's College London	Non-financial professional and personal	co-author of the BMJ article about 2019 CG144 Update https://www.bmj.com/content/369/bmj.m1565	2019	Declare and participate. Interest is out of scope
Susan Bewley (Chair of main panel and therapeutic subpanel)	Professor Emeritus (honorary) in Obstetrics & Women's Health, King's College London	Non-financial professional and personal	Co-author of the BMJ article on VITT 2021 https://www.bmj.com/content/375/bmj.n2195	Oct 2021	Declare and participate. Interest is out of scope

Expert advisory main panel members

Name	Job title and organisation	Type of interest	Description of interest	Relevant dates	Comments
Lewis Andrews (Member on main panel)	Head of Quality Improvement & Professional Standards - Advanced Paramedic, East	N/A	None	N/A	Declare and participate.

Name	Job title and organisation	Type of interest	Description of interest	Relevant dates	Comments
	of England Ambulance Service				
Dr James Bolton (Member on main panel)	Chair of the Faculty of Liaison Psychiatry, Royal College of Psychiatrists	Non-financial professional and personal	Co-authored: Alternatives to emergency departments for mental health assessments during the COVID-19 pandemic: Dr Nehal Parmar & Dr Jim Bolton August 2020 The Faculty of Liaison Psychiatry	August 2020	Declare and participate. Open declaration is sufficient mitigation.
Dr James Bolton (Member on main panel)	Chair of the Faculty of Liaison Psychiatry, Royal College of Psychiatrists	Non-financial professional and personal	Co-authored college covid guidelines that pertain to liaison psychiatry services: https://www.rcpsych.ac.uk/about-us/responding-to-covid-19/responding-to-covid-19-guidance-for-clinicians/community-and-inpatient-services/liaison-psychiatry-services	2020	Declare and participate. Open declaration is sufficient mitigation
Dr James Bolton (Member on main panel)	Chair of the Faculty of Liaison Psychiatry, Royal College of Psychiatrists	Non-financial professional and personal	I have submitted cases to the CoroNerve surveillance study therefore am listed as a co-author on PubMed in relation to: Neurological and neuropsychiatric complications of COVID-19 in 153 patients: a UK-wide surveillance study.	June 2020	Declare and participate. Open declaration is sufficient mitigation
Said Burale (Member on main panel)	Lay member	N/A	None	N/A	Declare and participate.
Margred Capel (Member on main panel since January 2022)	Consultant in Palliative Medicine, City Hospice/Velindre Hospital	Non-financial professional and personal	Training Programme Director for palliative medicine in Wales started 2019 - ongoing, this is an education role through HEIW, salaried since 2020 as part of my working sessions/within my job plan Clinical Director for City Hospice (does not attract any additional financial recompense)	Start: 2019 Ongoing	Declare and participate Interest is non-specific
Margred Capel (Member on main panel since January 2022)	Consultant in Palliative Medicine, City Hospice/Velindre Hospital	Non-financial professional and personal	Honorary Senior Lecturer Cardiff University - no financial benefit 2019-2022	Start: 2019 End: 2022	Declare and participate Interest is non-specific
Kim Drummond (Member on main panel)	Senior District Nurse, University Hospitals Birmingham NHS Foundation Trust	N/A	None	N/A	Declare and participate.
Lesley Durham	Director and Lead Nurse,	N/A	None	N/A	Declare and participate.

Name	Job title and organisation	Type of interest	Description of interest	Relevant dates	Comments
(Member on main panel)	North of England Critical Care Network (NoECCN), National Outreach Forum (NOrF)				
Dr Sam Hare (Member on main panel)	Consultant Thoracic Radiologist	Direct, financial	Ad hoc private practice reporting of radiology scans	February 2011 – present	Declare and participate. Interest is non-specific
Dr Sam Hare (Member on main panel)	Consultant Thoracic Radiologist	Direct, financial	Founder/Director of a cardiothoracic teleradiology reporting service (Heart&Lung Imaging Ltd)	June 2020 – present	Declare and participate. Interest is non-specific
Dr Rekash Inamdar (Member on main panel)	GP Partner / Operation Manager, Oakmeadow Surgery (GP Partner) / Giltbrook Care Home (Operations Manager)	Direct, financial	Giltbrook Carehomes - Operations Manager for Care Home since August 2018 - As the OM of the organisation, I am responsible for the day to day running of the care home and essential act as the Care Home Manager.	August 2018 – present	Declare and participate. Salaried role. Declaration is sufficient mitigation.
Dr Rekash Inamdar (Member on main panel)	GP Partner / Operation Manager, Oakmeadow Surgery (GP Partner) / Giltbrook Care Home (Operations Manager)	Non-financial professional and personal	June 2020 -Chair of Nottinghamshire Skills of Care - My role with Skills for Care as the Nottinghamshire Chair for the Registered Manager's Network is to support Registered Managers and Providers of social care (i.e., LD homes, nursing homes, residential homes, and domiciliary care services).	June 2020 – present	Declare and participate. Interest is non-specific
Dr Rekash Inamdar (Member on main panel)	GP Partner / Operation Manager, Oakmeadow Surgery (GP Partner) /	Non-financial professional and personal	October 2019 - Next Generation GP East Midlands Co-Lead	October 2019 – present	Declare and participate. Interest is non-specific

Name	Job title and organisation	Type of interest	Description of interest	Relevant dates	Comments
	Giltbrook Care Home (Operations Manager)				
Prof Lesley Kavi (Member on main panel)	General Practitioner, Solihull Healthcare Partnership	Direct, financial	I am currently the RCGP Syncope Clinical champion, and the project is due to finish in May 2021. This is a paid role.	June 2018- May 2021	Declare and participate. Interest is non-specific
Prof Lesley Kavi (Member on main panel)	General Practitioner, Solihull Healthcare Partnership	Non-financial professional and personal interest	Chair of PoTS UK, a UK based charity supporting patients with postural tachycardia syndrome.	2010 – present	Declare and participate. Interest is non-specific
Prof Lesley Kavi (Member on main panel)	General Practitioner, Solihull Healthcare Partnership	Direct, financial	Received payment for providing educational webinars in relation to fainting and blackouts) funded by Medtronic	2017 – present	Declare and participate. Interest is non-specific
Dr James Larcombe (Member on main panel)	GP Locum, County Durham/GP for Covid19 Clinical Assessment Service South Central Ambulance (CCAS-SCAS)	Direct, financial	Director of JMed Ltd – my own company – medical consultancy, locum work. Private clinical practice accounts to approximately 5% of total but I have not carried out any self-employed locum work for the last 10 months.	March 2009 – present	Declare and participate. Private practice is limited and not specific to condition under consideration.
Dr James Larcombe (Member on main panel)	GP Locum County Durham/GP for Covid19 Clinical Assessment Service South Central Ambulance (CCAS-SCAS)	Direct, financial	Shareholdings Glaxo Smith Kline PLC (non-voting shareholder).	Summer 2020 – present	Declare and participate Interest will be kept under review and exclusion from discussion of recommendations relating to COVID-19 drugs developed by Glaxo Smith Kline.

Name	Job title and organisation	Type of interest	Description of interest	Relevant dates	Comments
					Reviewed for Ivermectin and not a conflict as GSK do not manufacture
Dr James Larcombe (Member on main panel)	GP Locum County Durham/GP for Covid19 Clinical Assessment Service South Central Ambulance (CCAS-SCAS)	Direct, financial	Co-moderator NICE GP reference panel	March 2017 – present	Declare and participate. Interest is non-specific
Prof Diane Playford (Member on main panel)	Professor of Neurological Rehabilitation, University of Warwick	Non-financial professional and personal	Member of the YourCovidRecovery core working group representing the BSRM – contributed to sections on pain fatigue, and goal setting	June 2020 – present	Declare and participate. Not specific to content to date but will be kept under review depending on matter under consideration.
Prof Diane Playford (Member on main panel)	Professor of Neurological Rehabilitation, University of Warwick	Direct, financial	Medical consultancy in field of brain injury rehabilitation through private practice however no current private consultancy	July 2019 – present	Declare and participate. Interest is non-specific
Dr Vije Rajput (Member on main panel)	General Practitioner, Stonydelph Medical Practice, South East Staffordshire & Seisdon Peninsula CCG	Non-financial professional and personal	Committee member of Primary Health Care Specialist Group (PHCSG) of British Computer Society (BCS).	October 2020 – ongoing	Declare and participate. Interest is non-specific
Dr Vije Rajput (Member on main panel)	General Practitioner, Stonydelph Medical Practice, South East Staffordshire &	Non-financial professional and personal	Professional member of British Computer Society (BCS).	June 2021 – ongoing	Declare and participate. Interest is non-specific

Name	Job title and organisation	Type of interest	Description of interest	Relevant dates	Comments
	Seisdon Peninsula CCG				
Dr Vije Rajput (Member on main panel)	General Practitioner, Stonydelph Medical Practice, South East Staffordshire & Seisdon Peninsula CCG	Non-financial professional and personal	Publication: Telehealth and the COVID-19 Pandemic: International Perspectives and a Health Systems Framework for Telehealth Implementation to Support Critical Response. Basu, A; Kuziemy, C; Magdala de Araújo Novaes; Kleber, A; Sales, F; Al-Shorbaji, N; Florez-Arango, J; Gogia, B; Ho, K; Hunter, I; Iyengar, S; John, O; John, S; Kulatunga, G; Rajput, V; Ranatunga, P; Udayasankaran, J. Telehealth and the COVID-19 Pandemic: International Perspectives and a Health Systems Framework for Telehealth Implementation to Support Critical Response - PubMed (nih.gov)	2021	Declare and participate. Interest is non-specific
Dr Vije Rajput (Member on main panel)	General Practitioner, Stonydelph Medical Practice, South East Staffordshire & Seisdon Peninsula CCG	Non-financial professional and personal	Presentation: Post COVID-19: Is digital the future of primary care? Primary Health Care Specialist Group of the British Computer Society, 19 March 2021	March 2021	Declare and participate. Interest is non-specific
Elizabeth Rees (Member on main panel)	Lead Nurse for Palliative and End of Life Care, Leeds Teaching Hospitals	Non-financial professional and personal	I am the clinical lead for the National Audit of Care at the End of life (NACEL)	2017 – ongoing	Declare and participate. Interest is non-specific
Elizabeth Rees (Member on main panel)	Lead Nurse for Palliative and End of Life Care, Leeds Teaching Hospitals	Non-financial professional and personal	I am a specialist advisor inspector for the CQC	2019 – ongoing	Declare and participate. Interest is non-specific
Clare Rossall (Member on main panel)	NIV Specialist Practitioner Physiotherapist, University Hospitals Leicester	N/A	None	N/A	Declare and participate.
Mr Paul Twose (Member on main panel)	Consultant Therapist, Cardiff and Vale UHB	N/A	None	N/A	Declare and participate.

Name	Job title and organisation	Type of interest	Description of interest	Relevant dates	Comments
Prof Bee Wee (Non-voting member on main panel until December 2021)	Consultant in Palliative Medicine, Oxford University Hospitals NHS Foundation Trust	Direct, financial	Honorarium paid for virtual lectures in Hong Kong & Canada concerning wider issues around palliative and end of life care.	November 2020 – December 2020	Declare and participate. Interest is non-specific
Prof Bee Wee (Non-voting member on main panel until December 2021)	Consultant in Palliative Medicine, Oxford University Hospitals NHS Foundation Trust	Direct, financial	Honorarium paid for expert review of grant applications to Oak Foundation relating to palliative care services - none are COVID related.	December 2020	Declare and participate. Interest is non-specific
Prof Bee Wee (Non-voting member on main panel until December 2021)	Consultant in Palliative Medicine, Oxford University Hospitals NHS Foundation Trust	Direct, financial	Honorarium paid for expert review of grant applications to Nordforsk: Nordic programme for interdisciplinary research – non COVID related.	August 2020	Declare and participate. Interest is non-specific
Prof Bee Wee (Non-voting member on main panel until December 2021)	Consultant in Palliative Medicine, Oxford University Hospitals NHS Foundation Trust	Direct, financial	Honorarium paid for expert review of grant applications related to older age– Singapore Medical Research Council – non COVID related.	August 2020	Declare and participate. Interest is non-specific
Prof Bee Wee (Non-voting member on main panel until December 2021)	Consultant in Palliative Medicine, Oxford University Hospitals NHS Foundation Trust	Direct, financial	Honorarium paid for expert review – Irish Health Services Executive. I chaired the Expert Advisory Group for reviewing and making recommendations to strengthen clinical governance arrangements for children with life limiting conditions towards the end of life.	2020	Declare and participate. Interest is non-specific
Prof Bee Wee (Non-voting member on main panel until December 2021)	Consultant in Palliative Medicine, Oxford University Hospitals NHS Foundation Trust	Non-financial professional and personal	National Clinical Director for Palliative and End of Life Care, NHS England and NHS Improvement	2013 – present	Declare and participate Interest will be kept under review, can participate in discussion but withdraw from recommendation drafting for palliative care and end of life.

Name	Job title and organisation	Type of interest	Description of interest	Relevant dates	Comments
					Member is acting in an advisory capacity and is a non-voting member.
Prof Bee Wee (Non-voting member on main panel until December 2021)	Consultant in Palliative Medicine, Oxford University Hospitals NHS Foundation Trust	Non-financial professional and personal	Associate Professor of Palliative Medicine, Nuffield Department of Medicine, Oxford University	2015 – present	Declare and participate. Interest is non-specific
Prof Bee Wee (Non-voting member on main panel until December 2021)	Consultant in Palliative Medicine, Oxford University Hospitals NHS Foundation Trust	Non-financial professional and personal	Co-opted Trustee: Faculty of Medical Leadership and Management	2019 - present	Declare and participate. Interest is non-specific

Expert advisory main panel and therapeutic subpanel members

Name	Job title and organisation	Type of interest	Description of interest	Relevant dates	Comments
Dr Jay Banerjee (Member on main and therapeutic subpanel from January 2022 onwards)	Consultant and Honorary Professor in Geriatric Emergency Medicine, University Hospitals of Leicester NHS Trust	Direct financial	Director - Jay Banerjee Consultancy Limited. Offer training in geriatric emergency care, patient safety and improvement coaching to healthcare providers. Deliver for NHS Elect, EMAHSN, universities in UK and abroad. Clinical lead for NHS Elect on national frailty networks, this work is undertaken through the consultancy. I receive payment for this work. No COVID-related funded activity.	May 2016 - ongoing	Declare and participate. Interest is non-specific and no funding related to COVID-19.
Dr Jay Banerjee (Member on main and therapeutic subpanel from January 2022)	Consultant and Honorary Professor in Geriatric Emergency Medicine, University	Non-financial professional and personal	Study of the impact of COVID on frail older people. Leicester's ED has the largest dataset on frail older people of any emergency department, maybe internationally. We published this paper on frailty and COVID outcomes in July'20 and although there is no ongoing programme of work, I remain interested in this area and keen to explore it further.	April 2020 - ongoing	Declare and participate Interest is specific and declaration is sufficient mitigation and will be kept under review.

Name	Job title and organisation	Type of interest	Description of interest	Relevant dates	Comments
	Hospitals of Leicester NHS Trust		Owen RK, Conroy SP, Taub N, Jones W, Bryden D, Pareek M, Faull C, Abrams KR, Davis D, Banerjee J. Comparing associations between frailty and mortality in hospitalised older adults with or without COVID-19 infection: a retrospective observational study using electronic health records. Age Ageing. 2021 Feb 26;50(2):307-316. doi: 10.1093/ageing/afaa167. PMID: 32678866; PMCID: PMC7454252.		
Dr Jay Banerjee (Member on main and therapeutic subpanel from January 2022)	Consultant and Honorary Professor in Geriatric Emergency Medicine, University Hospitals of Leicester NHS Trust	Non-financial professional and personal	I have not received any funding for any COVID related work. I have never received any research funding for drug trials and only do health services research and delivery.	February 2021	Declare and participate Interest is non-specific
Dr Jay Banerjee (Member on main and therapeutic subpanel from January 2022)	Consultant and Honorary Professor in Geriatric Emergency Medicine, University Hospitals of Leicester NHS Trust	Non-financial professional and personal	Co-author: Human factors issues of working in personal protective equipment during the COVID-19 pandemic (lboro.ac.uk)	2020	Declare and participate Interest is non-specific
Dr Philip Bell (Member on main and therapeutic subpanel)	Lay member	Non-financial professional and personal	Member of the PPI Group at Sheffield University The PRIEST study: Pandemic Respiratory Infection Emergency System Triage Planned investigation: We aim to optimise the triage of people using the emergency care system (111 and 999 calls, ambulance conveyance, or hospital emergency department) with suspected respiratory infections during the COVID-19 pandemic and identify the most accurate triage method for predicting severe illness among patients using the urgent and emergency care system for suspected respiratory infection.	June 2020 – present	Declare and participate. Interest is out of scope
Eileen Burns (Member on main and therapeutic)	Consultant Physician, Leeds Teaching University	Non-financial professional and personal	Co-author of BGS guidelines on managing Covid in care homes, published on BGS website and in Age and Ageing	June 2021	Declare and participate.

Name	Job title and organisation	Type of interest	Description of interest	Relevant dates	Comments
subpanel from February 2022)			https://www.bgs.org.uk/resources/covid-19-managing-the-covid-19-pandemic-in-care-homes		Open declaration is sufficient mitigation
Prof George Davey Smith (Member on main and therapeutic subpanel)	Professor of Clinical Epidemiology, University of Bristol	Non-financial professional and personal	Griffith G, et al. Collider bias undermines our understanding of COVID-19 disease risk and severity. Nature Communications 2020; 11:5749	2020	Declare and participate. Interest is non-specific
Prof George Davey Smith (Member on main and therapeutic subpanel)	Professor of Clinical Epidemiology, University of Bristol	Non-financial professional and personal and indirect-financial	I am on the Scientific Advisory Board for the National Institute for Health Research grant for the following study: "Characterisation, determinants, mechanisms and consequences of the long-term effects of COVID-19: providing the evidence base for health care services". Lead applicant is Nish Chaturvedi and University College London.	March 2021-2024	Declare and participate. Interest is out of scope
Prof. George Davey Smith (Member on main and therapeutic subpanel)	Professor of Clinical Epidemiology, University of Bristol	Non-financial professional and personal	Davies NM, et al. Implications of selection bias for the COVID Symptom Tracker Study. Science 2020, in press.	2020	Declare and participate. Interest is non-specific
Prof. George Davey Smith (Member on main and therapeutic subpanel)	Professor of Clinical Epidemiology, University of Bristol	Non-financial professional and personal	Dooley H, et al. ACE inhibitors, ARBs and other anti-hypertensive drugs and novel COVID-19: An association study from the COVID Symptom tracker app in 2,215,386 individuals. SSRN 2020, on-line. https://ssrn.com/abstract=3583469	2020	Declare and participate. Interest is non-specific
Prof. George Davey Smith (Member on main and therapeutic subpanel)	Professor of Clinical Epidemiology, University of Bristol	Non-financial professional and personal	Davey Smith G, et al. Shielding from covid-19 should be stratified by risk . BMJ 2020;369:m2063	2020	Declare and participate. Interest is non-specific
Prof. George Davey Smith (Member on main and therapeutic subpanel)	Professor of Clinical Epidemiology, University of Bristol	Non-financial professional and personal	Davey Smith George et al. Covid-19's known unknowns BMJ 2020; 371: m3979	2020	Declare and participate. Interest is non-specific
Prof. George Davey Smith	Professor of Clinical Epidemiology,	Non-financial professional and personal	Alwan NA, et al. Evidence informing the UK's COVID-19 public health response must be transparent. The Lancet 2020; doi.org/10.1016/S0140-6736(20)30667-X	2020	Declare and participate. Interest is non-specific

Name	Job title and organisation	Type of interest	Description of interest	Relevant dates	Comments
(Member on main and therapeutic subpanel)	University of Bristol				
Prof. George Davey Smith (Member on main and therapeutic subpanel)	Professor of Clinical Epidemiology, University of Bristol	Non-financial professional and personal	Peto J, et al. Universal weekly testing as the UK COVID-19 lockdown exit strategy. The Lancet 2020; 395:1420-1421 and https://royalsocietypublishing.org/doi/full/10.1098/rsos.200915	2020	Declare and participate. Interest is non-specific
Prof. George Davey Smith (Member on main and therapeutic subpanel)	Professor of Clinical Epidemiology, University of Bristol	Non-financial professional and personal	Dorling D, Brookes D, Davey Smith G. Why are coronavirus rates rising in some areas of England and not others? The Conversation. 1st October 2020. https://theconversation.com/why-are-coronavirus-rates-rising-in-some-areas-of-england-and-not-others-147160	2020	Declare and participate. Interest is non-specific
Prof. George Davey Smith (Member on main and therapeutic subpanel)	Professor of Clinical Epidemiology, University of Bristol	Non-financial professional and personal	Davey Smith G. Covid 19: What do we know? Workers Liberty 1st November 2020	2020	Declare and participate. Interest is non-specific
Prof. George Davey Smith (Member on main and therapeutic subpanel)	Professor of Clinical Epidemiology, University of Bristol	Non-financial professional and personal	Dorling D, et al. Why is COVID-19 more severe in the north of England? The story in four graphs. The Conversation, 2nd December 2020.	2020	Declare and participate. Interest is non-specific
Prof. George Davey Smith (Member on main and therapeutic subpanel)	Professor of Clinical Epidemiology, University of Bristol	Non-financial professional and personal interest	Davey Smith G, et al. Responding to the “known unknowns” of covid-19. BMJ 19th January 2021 https://blogs.bmj.com/bmj/2021/01/19/responding-to-the-known-unknowns-of-covid-19/	2021	Declare and participate. Interest is non-specific
Dr Michael Davies (Member on main and therapeutic subpanel)	Clinical Director for Thoracic Services & Consultant Physician, Royal Papworth Hospital	Non-financial professional and personal	Clinical Lead for the British Thoracic Society Acute Non-invasive Ventilation Audit. Presented the findings of successive audits at national conferences (BTS Winter Meetings); Co -proposed NCEPOD's study into acute NIV and ('Inspiring Change' 2017); Spoken at regional Respiratory and ICU meetings (none for payment) Co-authored a review of NIV guidelines and audit development:	2012-ongoing	Declare and participate. Interest is non-specific

Name	Job title and organisation	Type of interest	Description of interest	Relevant dates	Comments
			<p>Davies MG, Juniper MC. Lessons learnt from the National Confidential Enquiry into Patient Outcome and Death: Acute non-invasive ventilation. Thorax 2018;73:904-907</p> <p>Lessons learnt from the National Confidential Enquiry into Patient Outcome and Death: Acute non-invasive ventilation Thorax (bmj.com)</p>		
Dr Michael Davies (Member on main and therapeutic subpanel)	Clinical Director for Thoracic Services & Consultant Physician, Royal Papworth Hospital	Non-financial professional and personal	Regional representative (complex home ventilation services), Specialised Respiratory Clinical Reference Group, NHS England.	2019-ongoing	<p>Declare and participate.</p> <p>Interest is non-specific</p>
Dr Michael Davies (Member on main and therapeutic subpanel)	Clinical Director for Thoracic Services & Consultant Physician, Royal Papworth Hospital	Non-financial professional and personal and indirect-financial	Chief Investigator, MATHS study. Single centre study studying the use of a novel form of blood gas testing (mathematical arterialisation of venous samples). Funded by Obimedical Ltd (£30,000). All funding towards study. No personal financial interest.	2018-2021	<p>Declare and participate.</p> <p>Interest is non-specific</p>
Dr Michael Davies (Member on main and therapeutic subpanel)	Clinical Director for Thoracic Services & Consultant Physician, Royal Papworth Hospital	Non-financial professional and personal and indirect-financial	<p>Local PI for the multi-centre HEAL-COVID study assessing drugs to reduce deaths and readmission for patients who are recovering after hospitalisation for COVID-19.</p> <p>Drugs being considered at this stage: Atorvastatin and Apixaban</p> <p>I am not receiving any funding for the study. The study is funded via the NIHR (organisational costs will be paid to Royal Papworth Hospital).</p> <p>We have yet to fully register. Expected duration to 31/01/2024.</p>	May 2021-2024	<p>Declare and participate.</p> <p>Role of therapeutics for long-term effect of COVID-19 is out of scope for this guideline.</p>
Dr Michael Davies (Member on main and therapeutic subpanel)	Clinical Director for Thoracic Services & Consultant Physician, Royal	Non-financial professional and personal and indirect-financial	Senior author on a paper describing the Royal Papworth Hospital experience of the first COVID wave with particular reference to the use of respiratory support. The study outlines a positive single centre experience using CPAP therapy for selected patients.	2020	<p>Declare and participate.</p> <p>Interest is specific but was not included in the evidence base for</p>

Name	Job title and organisation	Type of interest	Description of interest	Relevant dates	Comments
	Papworth Hospital		Wozniak, DR, Rubino A, Tan ALW, Jones NL, Webb ST, Vuylsteke A, Palas A, Quinnell TG, Smith IE, Davies MG. Positive Role of Continuous Positive Airway Pressure for Intensive Care Unit Patients with Severe Hypoxaemic Respiratory Failure Due to COVID-19 Pneumonia: A Single Centre Experience. Journal of the Intensive Care Society. 2020.		respiratory support review. The content was not deemed to prejudice the panel member from approaching the evidence objectively.
Dr Michael Davies (Member on main and therapeutic subpanel)	Clinical Director for Thoracic Services & Consultant Physician, Royal Papworth Hospital	Non-financial professional and personal and indirect-financial	Co-author, East of England Respiratory & Critical Care Networks Guidance for the use of CPAP or NIV for patients Acute Hypoxaemic Respiratory Failure associated with COVID-19 (November 2020) A significant part of this document was subsequently used to compile the London Network guidance, though I did not contribute to that	Nov 2020	Declare and participate. Interest is non-specific
Dr Michael Davies (Member on main and therapeutic subpanel)	Clinical Director for Thoracic Services & Consultant Physician, Royal Papworth Hospital	Non-financial professional and personal and indirect-financial	I contributed to the BTS guidance on the use of Respiratory Support in COVID and the more recent guidance for Respiratory Support Units	2021	Declare and participate. Interest is non-specific
Prof Jane Eddleston (Member on main and therapeutic subpanel until October 2021)	Consultant in Intensive Care, Chair of NHS England Adult Critical Care Clinical Reference Group, Manchester University NHS Foundation Trust	Non-financial professional and personal	Chair of NHS England's CRG for Adult Critical Care	2013 – present	Declare and participate. Interest is non-specific
Dr Nandan Gautam (Member on main and therapeutic)	Consultant in General Medicine and Intensive Care, Queen Elizabeth	Non-financial professional and personal	Publication: Lung function and breathing patterns in hospitalised COVID-19 survivors: a review of post-COVID-19 Clinics	Sept 2021	Declare and participate Interest is out of scope

Name	Job title and organisation	Type of interest	Description of interest	Relevant dates	Comments
subpanel since October 2021)	Hospital Birmingham		Lung function and breathing patterns in hospitalised COVID-19 survivors: a review of post-COVID-19 Clinics - PubMed (nih.gov)		
Dr Nandan Gautam (Member on main and therapeutic subpanel since October 2021)	Consultant in General Medicine and Intensive Care, Queen Elizabeth Hospital Birmingham	Non-financial professional and personal	Publication: Medium-term outcome of severe to critically ill patients with SARS-CoV-2 infection Medium-term outcome of severe to critically ill patients with SARS-CoV-2 infection - PubMed (nih.gov)	April 2021	Declare and participate Interest will be kept under review for future recommendations.
Dr Nandan Gautam (Member on main and therapeutic subpanel since October 2021)	Consultant in General Medicine and Intensive Care, Queen Elizabeth Hospital Birmingham	Non-financial professional and personal	Publication: Lung Function and Breathing Patterns in Hospitalised COVID-19 Survivors: a Review of Post-COVID-19 Clinics Lung function and breathing patterns in hospitalised COVID-19 survivors: a review of post-COVID-19 Clinics - PubMed (nih.gov)	April 2021	Declare and participate Interest is out of scope.
Dr Nandan Gautam (Member on main and therapeutic subpanel since October 2021)	Consultant in General Medicine and Intensive Care, Queen Elizabeth Hospital Birmingham	Non-financial professional and personal	Publication: Assembly Line ICU: What the Long Shops taught us about managing surge capacity for COVID-19 Assembly Line ICU: what the Long Shops taught us about managing surge capacity for COVID-19 BMJ Open Quality	December 2020	Declare and participate Interest will be kept under review for future recommendations.
Dr Nandan Gautam (Member on main and therapeutic subpanel since October 2021)	Consultant in General Medicine and Intensive Care, Queen Elizabeth Hospital Birmingham	Non-financial professional and personal	Publication: After Care of Survivors of COVID-19—Challenges and a Call to Action [PDF] After Care of Survivors of COVID-19—Challenges and a Call to Action Semantic Scholar	August 2020	Declare and participate Interest will be kept under review for future recommendations.
Dr Nandan Gautam (Member on main and therapeutic subpanel since October 2021)	Consultant in General Medicine and Intensive Care, Queen Elizabeth Hospital Birmingham	Non-financial professional and personal	I am a contributing author to online resources https://www.postcovidsyndromesol.nhs.uk/	Ongoing	Declare and participate Interest is out of scope
Dr Nandan Gautam (Member on main and	Consultant in General Medicine and Intensive	Non-financial professional and personal	I will be submitting an application for grants for trials related to covid recovery but yet to be submitted. These are for observational studies only so far.	Ongoing	Declare and participate

Name	Job title and organisation	Type of interest	Description of interest	Relevant dates	Comments
therapeutic subpanel since October 2021)	Care, Queen Elizabeth Hospital Birmingham				Declaration is sufficient mitigation and will be kept under review
Dr Nandan Gautam (Member on main and therapeutic subpanel since October 2021)	Consultant in General Medicine and Intensive Care, Queen Elizabeth Hospital Birmingham	Non-financial professional and personal	I lead the West Midlands ICS post covid care pathway	Ongoing	Declare and participate Interest is out of scope
Dr Jim Gray (Member on main and therapeutic subpanel since June 2022)	Consultant Medical Microbiologist, Birmingham Women's & Children's NHS Foundation Trust	Direct-financial	Co-applicant: Healthcare Infection Society small grant (reference SRG/2020/09/001). Walker K, et al. Maternity services response to the COVID-19 pandemic: how PHE guidance was implemented and what we can learn for the future. Awarded 19.11.2020	19/11/2020-18/11/2021	Declare and participate Declaration is sufficient.
Dr Jim Gray (Member on main and therapeutic subpanel since June 2022)	Consultant Medical Microbiologist, Birmingham Women's & Children's NHS Foundation Trust	Direct-financial	Editor-in-Chief, Journal of Hospital Infection. I receive payment of £10k per year for this work. This journal has published, and continues to publish, a large number of COVID-19-related papers.	01/12/2014-30/09/2022	Declare and participate The journal will review all articles submitted. The payment is for administrative time and not to accept a particular viewpoint.
Dr Jim Gray (Member on main and therapeutic subpanel since June 2022)	Consultant Medical Microbiologist, Birmingham Women's & Children's NHS Foundation Trust	Non-financial professional and personal	Editor in Chief responsibility for COVID-19 related papers submitted to the International Journal of Antimicrobial Agents. This role is unpaid.	01/04/2020-ongoing	Declare and participate The journal will review all articles submitted.
Dr Jim Gray (Member on main and therapeutic subpanel since June 2022)	Consultant Medical Microbiologist, Birmingham Women's &	Non-financial professional and personal	Co-author/presented of COVID-19-related articles as follows: Gray J. How has COVID changed my field? COVID-19: Challenges and solutions : Healthcare Infection Society webinar series. Presented live on 16.06.2021.	16/06/2021	Declare and participate Interest will be kept under review depending on matter under consideration.

Name	Job title and organisation	Type of interest	Description of interest	Relevant dates	Comments
	Children's NHS Foundation Trust				
Dr Jim Gray (Member on main and therapeutic subpanel since June 2022)	Consultant Medical Microbiologist, Birmingham Women's & Children's NHS Foundation Trust	Non-financial professional and personal	Prescott K, Gray J, Mahida N, Winzor G, Wilkinson M. Lessons learned from the COVID-19 pandemic through the JHI and IPIP . J Hosp Infect 2022;119:80-3.	01/01/2022	Declare and participate Interest will be kept under review depending on matter under consideration.
Dr Jim Gray (Member on main and therapeutic subpanel since June 2022)	Consultant Medical Microbiologist, Birmingham Women's & Children's NHS Foundation Trust	Non-financial professional and personal	Hanley S, Jones A, Baxter E, Sharkey D, Gray J, Walker K. Implementation of Public Health England Infection Prevention and Control Guidance in Maternity Units in Response to the COVID-19 Pandemic . J Hosp Infect. In press	27/04/2022	Declare and participate Interest will be kept under review depending on matter under consideration.
Dr Jim Gray (Member on main and therapeutic subpanel since June 2022)	Consultant Medical Microbiologist, Birmingham Women's & Children's NHS Foundation Trust	Non-financial professional and personal	Hanley SJ, Jones AB, Baxter E, Sharkey D, Gray J, Walker KF. Implementation of COVID-19 Public Health England guidance in maternity. Accepted for e-poster presentation at the RCOG World Congress 2022, 13-15 June 2022.	13/06/2022	Declare and participate Interest will be kept under review depending on matter under consideration.
Dr Daniel Horner (Member on main and therapeutic subpanel)	Consultant in Emergency and Critical Care Medicine, Salford Royal NHS Foundation Trust	Non-financial professional and personal	I have given several webinars recently on the topic in question for Thrombosis UK and published several blog posts on an open access medical education platform https://www.letstalkclots.com/ https://www.stemlynsblog.org/vte-and-covid-19-would-you-like-to-know-more/	January 2020 – October 2020	Declare and participate. Declaration is sufficient mitigation.
Dr Daniel Horner (Member on main and therapeutic subpanel)	Consultant in Emergency and Critical Care Medicine, Salford Royal NHS Foundation Trust	Non-financial professional and personal	I am co-chief investigator for an active NIHR HTA research project looking at the clinical and cost effectiveness of venous thromboembolism risk assessment tools.	June 2019 – ongoing	Declare and participate. Interest is not specific to the recommendations to date. Exclusion from future discussions as and when needed.

Name	Job title and organisation	Type of interest	Description of interest	Relevant dates	Comments
Dr Daniel Horner (Member on main and therapeutic subpanel)	Consultant in Emergency and Critical Care Medicine, Salford Royal NHS Foundation Trust	Non-financial professional and personal	I was a topic expert for NG158	Sept 2018 – March 2020	Declare and participate. Interest is non-specific
Dr Daniel Horner (Member on main and therapeutic subpanel)	Consultant in Emergency and Critical Care Medicine, Salford Royal NHS Foundation Trust	Non-financial professional and personal	I was a topic expert for the recent British Thoracic Society guidelines on the outpatient management of suspected or confirmed pulmonary embolism	August 2017 – August 2019	Declare and participate. Interest is non-specific
Dr Daniel Horner (Member on main and therapeutic subpanel)	Consultant in Emergency and Critical Care Medicine, Salford Royal NHS Foundation Trust	Non-financial professional and personal	I am a current Professor of the Royal College of Emergency Medicine. This is an unfunded nominal post.	October 2017 - ongoing	Declare and participate. Interest is non-specific
Dr Daniel Horner (Member on main and therapeutic subpanel)	Consultant in Emergency and Critical Care Medicine, Salford Royal NHS Foundation Trust	Non-financial professional and personal	I have written several blog articles on the use of tocilizumab in COVID19 for a free open access medical education website – the links to all three are within the below: https://www.stemlynsblog.org/tocilizumabulous-a-special-offer-on-il-6-with-tocilizumab/	February 2021	Declare and participate. Declaration is sufficient mitigation. The content was not deemed to prejudice the panel member from approaching the evidence objectively.
Dr Daniel Horner (Member on main and therapeutic subpanel)	Consultant in Emergency and Critical Care Medicine, Salford Royal NHS Foundation Trust	Non-financial professional and personal	BMJ editorial on target oxygen saturations for acutely ill medical patients: https://www.bmj.com/content/363/bmj.k4436	2018	Declare and participate. Interest is non-specific and from 2018.
Dr Daniel Horner (Member on main and therapeutic subpanel)	Consultant in Emergency and Critical Care Medicine, Salford Royal NHS Foundation Trust	Non-financial professional and personal	Our site participated in the RECOVERY-RS trial looking at use of non-invasive ventilation strategies for the management of acute COVID19. I am the research lead for our critical care unit - as such, I participated in this research through identification of potentially eligible participants and contact with the research nursing team. I	01/01/2022-20/01/2022	Declare and participate. Despite being specific to the non-invasive respiratory support update the member's

Name	Job title and organisation	Type of interest	Description of interest	Relevant dates	Comments
			<p>also highlighted this trial to my colleagues at research meetings, within the portfolio of trials we recruit to. I was not principle investigator at our site.</p> <p>Two of my colleagues at Salford are authors on the recent JAMA paper. I am not involved in authorship of any manuscripts.</p> <p>Perkins GD, Ji C, Connolly BA, et al. Effect of Noninvasive Respiratory Strategies on Intubation or Mortality Among Patients With Acute Hypoxemic Respiratory Failure and COVID-19: The RECOVERY-RS Randomized Clinical Trial. <i>JAMA</i>. 2022;327(6):546–558. doi:10.1001/jama.2022.0028 https://jamanetwork.com/journals/jama/fullarticle/2788505</p>		only involvement was identifying participants. Declaration is sufficient mitigation.
Dr Daniel Horner (Member on main and therapeutic subpanel)	Consultant in Emergency and Critical Care Medicine, Salford Royal NHS Foundation Trust	Non-financial professional and personal	<p>I have co-authored 2 published articles on the use of awake prone positioning:</p> <p>Bell J, Horner D. BET 1: Prone positioning of awake patients with acute hypoxaemic respiratory failure. <i>Emerg Med J</i>. 2020 Jun;37(6):379-381. doi: 10.1136/emered-2020-209962.2. PMID: 32487709. https://pubmed.ncbi.nlm.nih.gov/32487709/</p>	2020	<p>Declare and participate.</p> <p>Interest is specific but was not included in the evidence base for awake prone positioning due to study type.</p> <p>The content was not deemed to prejudice the panel member from approaching the evidence objectively.</p>
Dr Daniel Horner (Member on main and therapeutic subpanel)	Consultant in Emergency and Critical Care Medicine, Salford Royal NHS Foundation Trust	Non-financial professional and personal	<p>Carley S, Horner D, Body R, et al Evidence-based medicine and COVID-19: what to believe and when to change <i>Emergency Medicine Journal</i> 2020;37:572-575. https://emj.bmj.com/content/37/9/572</p>	2020	<p>Declare and participate.</p> <p>Interest is non-specific to awake prone positioning and non-invasive respiratory support</p>
Prof Philip Howard (Member on main and therapeutic subpanel)	Consultant Pharmacist, Leeds Teaching Hospitals NHS Trust	Non-financial professional and personal	<p>University academic & clinical pharmacist published extensively in the field but nonspecific to COVID-19.</p>	2009 – ongoing	<p>Declare and participate.</p> <p>Interest is non-specific</p>
Prof Philip Howard	Consultant Pharmacist, Leeds Teaching	Non-financial professional and personal	<p>Antimicrobial Expert Advisory Board. Provide advice to RPS about AMR and antimicrobial stewardship. Occasional spokesperson.</p>	2016 – present	<p>Declare and participate.</p> <p>Interest is non-specific</p>

Name	Job title and organisation	Type of interest	Description of interest	Relevant dates	Comments
(Member on main and therapeutic subpanel)	Hospitals NHS Trust				
Prof Philip Howard (Member on main and therapeutic subpanel)	Consultant Pharmacist, Leeds Teaching Hospitals NHS Trust	Non-financial professional and personal	President of British Society of Antimicrobial Chemotherapy. BSAC provides free education and research funding on the responsible use of antibiotics to healthcare professionals, public and Parliamentarians within its charitable goals at a global level. Part of BSAC's income is from the pharmaceutical and diagnostics industry through unrestricted education grants. All financial elements dealt with by CEO and Treasurer.	April 2018 – April 2021	Declare and participate. Interest is non-specific
Prof Philip Howard (Member on main and therapeutic subpanel)	Consultant Pharmacist, Leeds Teaching Hospitals NHS Trust	Non-financial professional and personal and indirect-financial	Co-investigator: NIHR COVID Learning and Recovery call ref XP NIHR 132254 (PEACH study) - procalcitonin evaluation of antibiotic use in COVID-19 hospitalised patients. Funding goes to my employer.	Sept 2020-ongoing	Declare and participate. Interest is not specific to the recommendations to date. Exclusion from future discussions as and when needed.
Prof Philip Howard (Member on main and therapeutic subpanel)	Consultant Pharmacist, Leeds Teaching Hospitals NHS Trust	Non-financial professional and personal and indirect-financial	This is the 1st paper published as part of PEACH study: “Use of Procalcitonin during the First Wave of COVID-19 in the Acute NHS Hospitals: A Retrospective Observational Study” https://eprints.whiterose.ac.uk/173661/1/antibiotics-10-00516.pdf	May 2021	Declare and participate Interest is not specific to the recommendations to date. Will be kept under review.
Prof Philip Howard (Member on main and therapeutic subpanel)	Consultant Pharmacist, Leeds Teaching Hospitals NHS Trust	Direct Financial	I have a new role having moved from Leeds Teaching Hospitals NHS Trust to NHS England and NHS Improvement to become the North-East and Yorkshire Regional Antimicrobial Stewardship Lead.	October 2021	Declare and participate This is member's salaried position. The role is regional so the member can continue.
Prof Beverley Hunt (Member on main and therapeutic subpanel)	Professor/Consultant - Thrombosis and Haemostasis, Guy's and St Thomas' NHS Foundation Trust	Non-financial professional and personal	Member of WHO COVID-19 guidance development group	2021	Declare and participate. Interest is non-specific
Prof Beverley Hunt	Professor/Consultant - Thrombosis	Direct-non-financial	Medical Director of Thrombosis UK	2002 – present	Declare and participate.

Name	Job title and organisation	Type of interest	Description of interest	Relevant dates	Comments
(Member on main and therapeutic subpanel)	and Haemostasis, Guy's and St Thomas' NHS Foundation Trust				Interest is non-specific
Prof Beverley Hunt (Member on main and therapeutic subpanel)	Professor/Consultant - Thrombosis and Haemostasis, Guy's and St Thomas' NHS Foundation Trust	Non-financial professional and personal	Chair of the steering group of World Thrombosis Day	2019 - ongoing	Declare and participate. Interest is non-specific
Prof Beverley Hunt (Member on main and therapeutic subpanel)	Professor/Consultant - Thrombosis and Haemostasis, Guy's and St Thomas' NHS Foundation Trust	Non-financial professional and personal	I sit on the COVID-19 therapeutic anticoagulation therapy domain governance committee of REMAP-CAP.	2020 - present	Declare and participate. Declaration is sufficient mitigation as member acts in a governance role only.
Prof Beverley Hunt (Member on main and therapeutic subpanel)	Professor/Consultant - Thrombosis and Haemostasis, Guy's and St Thomas' NHS Foundation Trust	Non-financial professional and personal	Member of the thrombostasis subcommittee of UK COVID-19 experimental treatment group	2020 – present	Declare and participate. Declaration is sufficient mitigation.
Prof Beverley Hunt (Member on main and therapeutic subpanel)	Professor/Consultant - Thrombosis and Haemostasis, Guy's and St Thomas' NHS Foundation Trust	Non-financial professional and personal	Author of BMJ Editorial: Prophylactic anticoagulation for patients in hospital with covid-19 BMJ 2021; 372 doi: https://doi.org/10.1136/bmj.n487 (Published 19 February 2021)Cite this as: BMJ 2021;372:n487	February 2021	Declare and participate. Declaration is sufficient mitigation
Dr Tania Kalsi (Member on main and therapeutic subpanel until February 2022)	Consultant Geriatrician, Guys & St Thomas' NHS Foundation Trust	Non-financial professional and personal	Co-author to this consensus statement: British Geriatrics Society: https://www.bgs.org.uk/resources/covid-19-managing-the-covid-19-pandemic-in-care-homes	October 2020	Declare and participate. Interest is non-specific

Name	Job title and organisation	Type of interest	Description of interest	Relevant dates	Comments
Dr Tania Kalsi (Member on main and therapeutic subpanel until February 2022)	Consultant Geriatrician, Guys & St Thomas' NHS Foundation Trust	Non-financial professional and personal	Co-author to this consensus statement: T&F Group consensus convened by Dr Adrian Hayter, National Clinical Director for Older People, published via Hospital @Home society: https://static1.squarespace.com/static/5de6ce4b04d2c03cb18778df/t/6004bbfc9cabb86c70e62bed/1610923036505/Consensus+State+ment+-+Drug+Treatment+in+Community+Settings+for+COVID19+patients.pdf	January 2021	Declare and participate.
Dr Tania Kalsi (Member on main and therapeutic subpanel until February 2022)	Consultant Geriatrician, Guys & St Thomas' NHS Foundation Trust	Non-financial professional and personal	I have not co-authored any papers on COVID, but I have had posters at conferences for which abstracts have been published: Coles T, Crawley S, Martin F, Diem P, Patel J, Masterton J, Noble J, Wilson D, Perks C, Kalsi T. Reflections of a care home provider on the COVID-19 pandemic: A catalyst for integrated care. <i>Eur Geriatr Med</i> 2020;11:63(P136). https://doi.org/10.1007/s41999-020-00428-6	October 2020	Declare and participate. Interest is non-specific
Dr Tania Kalsi (Member on main and therapeutic subpanel until February 2022)	Consultant Geriatrician, Guys & St Thomas' NHS Foundation Trust	Non-financial professional and personal	Abstract reference: Kalsi T, Wilson D, Kalafatis C, Gough N, San Pedro C, Crawley S, Hall E, Patel J, Lawal A, Dallmeyer R. Using WhatsApp messaging platform to facilitate rapid multi-professional, multi-organisational support for care homes during the COVID-19 pandemic. <i>Eur Geriatr Med</i> 2020;11:73(P169). https://doi.org/10.1007/s41999-020-00428-6	October 2020	Declare and participate. Interest is non-specific
Dr Tania Kalsi (Member on main and therapeutic subpanel until February 2022)	Consultant Geriatrician, Guys & St Thomas' NHS Foundation Trust	Non-financial professional and personal	Abstract reference: Diem P, Kalsi T, Fleet J, Beckett N. Delirium and relative bradycardia is common in patients who die of COVID-19 in hospital <i>Eur Geriatr Med</i> 2020;11:74(P173). https://doi.org/10.1007/s41999-020-00428-6	October 2020	Declare and participate. Declaration is sufficient mitigation.
Dr Tania Kalsi	Consultant Geriatrician, Guys & St	Non-financial professional and personal	PROTECT-CH – in process of contracting as a PRINCIPLE Investigator. UK-wide NIHR funded clinical trial platform that will test several treatments intended to reduce the spread of COVID-19	May 2021	Declare and participate

Name	Job title and organisation	Type of interest	Description of interest	Relevant dates	Comments
(Member on main and therapeutic subpanel until February 2022)	Thomas' NHS Foundation Trust	and indirect-financial	within care homes, reduce risks of hospitalisation and death. Further information is at https://www.protect-trial.net/ NIHR funding goes to Nottingham Clinical Trials Unit, who provide 0.5PA funding to each Principal Investigator, which will be contracted via our employers. Therapeutics involved are currently going through MHRA so are still to be confirmed.		Interest will be kept under review depending on matter under consideration Study has not yet started.
Dr Lucy Lamb (Member on main and therapeutic subpanel)	Army Consultant Infectious Diseases and General Medicine, Royal Free London/Defence Medical Services	Non-financial professional and personal	COVID 19: Myocardial injury in Survivors. Knight DS et al. Circulation 2020 COVID-19: Myocardial Injury in Survivors - PubMed (nih.gov)	September 2020	Declare and participate. Interest is non-specific
Dr Lucy Lamb (Member on main and therapeutic subpanel)	Army Consultant Infectious Diseases and General Medicine, Royal Free London/Defence Medical Services	Non-financial professional and personal	Patterns of myocardial injury in recovered troponin-positive COVID19 patients assessed by cardiovascular magnetic resonance. Kotecha T et al. Heart J 2021. Patterns of myocardial injury in recovered troponin-positive COVID-19 patients assessed by cardiovascular magnetic resonance - PubMed (nih.gov)	February 2021	Declare and participate. Interest is non-specific
Dr Lucy Lamb (Member on main and therapeutic subpanel)	Army Consultant Infectious Diseases and General Medicine, Royal Free London/Defence Medical Services	Non-financial professional and personal	Defence Physician's Consensus statement on Hospital Care for COVID-19	February 2021	Declare and participate. Declaration is sufficient mitigation.
Dr Lucy Lamb (Member on main and therapeutic subpanel)	Army Consultant Infectious Diseases and General Medicine, Royal Free London/Defence Medical Services	Non-financial professional and personal	Clinical features and Acute Management in Adults. Khan N et al. Chapter. European Respiratory Society	March 2021	Declare and participate. Declaration is sufficient mitigation.

Name	Job title and organisation	Type of interest	Description of interest	Relevant dates	Comments
Dr Lucy Lamb (Member on main and therapeutic subpanel)	Army Consultant Infectious Diseases and General Medicine, Royal Free London/Defence Medical Services	Non-financial professional and personal	Clinical Guidance Committee Royal Free London – Author of the RFL COVID-19 Bundle of Care	March 2021	Declare and participate. Declaration is sufficient mitigation.
Dr Lucy Lamb (Member on main and therapeutic subpanel)	Army Consultant Infectious Diseases and General Medicine, Royal Free London/Defence Medical Services	Non-financial professional and personal and indirect-financial	Co-investigator on trials at Royal Free London. Funding goes to the institution: Insight-13/ITAC An International Multicenter, Adaptive, Randomized Double-Blind, Placebo-Controlled Trial of the Safety, Tolerability and Efficacy of Anti-Coronavirus Hyperimmune Intravenous Immunoglobulin for the Treatment of Adult Hospitalized Patients at Onset of Clinical Progression of COVID-19	Starts July 2021	Declare and participate Interest will be kept under review depending on the matter under consideration. This specific intervention is not currently being considered as part of this guideline.
Dr Lucy Lamb (Member on main and therapeutic subpanel)	Army Consultant Infectious Diseases and General Medicine, Royal Free London/Defence Medical Services	Non-financial professional and personal and indirect-financial	Co-investigator (funding goes to institution): Recovery (randomized evaluation of COVID-19 therapy) in relation to Tocilizumab, Regeneron’s antibody cocktail and Colchicine. I am also listed on the delegation log but have not been involved with patient recruitment for the Baricitinib arm of the trial.	October 2020-ongoing	Declare and partial exclusion Participate in discussion of evidence, exclusion from drafting of recommendations on Tocilizumab, Colchicine and Baricitinib. Specific to recommendations that were published in April 2021, May 2021, October 2021, November 2021 and April 2022. Will be kept under review and exclusion from future discussions as and when needed.
Dr Lucy Lamb	Army Consultant Infectious	Non-financial professional	Co-investigator (funding goes to institution):	October 2020-ongoing	Declare and partial exclusion

Name	Job title and organisation	Type of interest	Description of interest	Relevant dates	Comments
(Member on main and therapeutic subpanel)	Diseases and General Medicine, Royal Free London/Defence Medical Services	and personal and indirect-financial	Efficacy and Safety of Molnupiravir (MK-4482) in Hospitalized Adult Participants With COVID-19 (MK-4482-001) Efficacy and Safety of Molnupiravir (MK-4482) in Non-Hospitalized Adult Participants With COVID-19 (MK-4482-002)		Participate in discussion of evidence, exclusion from drafting of recommendations for molnupiravir. Associated publication included in the evidence base.
Dr Lucy Lamb (Member on main and therapeutic subpanel)	Army Consultant Infectious Diseases and General Medicine, Royal Free London/Defence Medical Services	Non-financial professional and personal and indirect-financial	Co-investigator (funding goes to institution): ISARIC – I was involved with early data and sample collection off patients only (no drug trials).	March 2020	Declare and participate Member involvement ended at data collection and was not specific to an intervention.
Dr Lucy Lamb (Member on main and therapeutic subpanel)	Army Consultant Infectious Diseases and General Medicine, Royal Free London/Defence Medical Services	Non-financial professional and personal and indirect-financial	Co-investigator (funding goes to institution): GS-US-540-5774/5773 Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Severe Coronavirus Disease (COVID-19)	December 2020	Declare and partial exclusion from recommendation drafting in 2021 review of remdesivir, and update of recommendations in May 2022. Participate in discussion of evidence, exclusion from drafting of recommendations for remdesivir. Associated publications included in the evidence base for recommendations on remdesivir published in 2021 and update in 2022.

Name	Job title and organisation	Type of interest	Description of interest	Relevant dates	Comments
					<p>Declare and participate in recommendation drafting for use of remdesivir for people not in hospital in 2022.</p> <p>Associated papers not included in the evidence base for review remdesivir for people not in hospital in 2022.</p>
Dr Lucy Lamb (Member on main and therapeutic subpanel)	Army Consultant Infectious Diseases and General Medicine, Royal Free London/Defence Medical Services	Non-financial professional and personal and indirect-financial	Co-investigator (funding goes to institution): Roche – COVACTA trial of Actemra/RoActemra in hospitalised patients with severe COVID-19 associated pneumonia	July 2020	<p>Declare and participate</p> <p>Interest will be kept under review depending on the matter under consideration.</p> <p>This specific intervention is not currently being considered as part of this guideline.</p>
Dr Lucy Lamb (Member on main and therapeutic subpanel)	Army Consultant Infectious Diseases and General Medicine, Royal Free London/Defence Medical Services	Non-financial professional and personal	<p>I have been listed as a collaborator but not a writing group author for the following publication:</p> <p>Convalescent plasma in patients admitted to hospital with COVID-19 (RECOVERY): a randomised controlled, open-label, platform trial. RECOVERY Collaborative Group. LANCET 2021. PMID:34000257.</p>	May 2021	<p>Declare and participate</p> <p>Interest will be kept under review depending on the matter under consideration.</p> <p>This specific intervention is not currently being considered as part of this guideline.</p>
Dr Lucy Lamb (Member on main and therapeutic subpanel)	Army Consultant Infectious Diseases and General Medicine, Royal Free London/Defence Medical Services	Non-financial professional and personal	<p>I have been listed as a collaborator but not a writing group author for the following publication:</p> <p>Tocilizumab in patients admitted to hospital with COVID-19 (RECOVERY): a randomised controlled, open-label, platform trial. RECOVERY Collaborative Group. LANCET 2021. PMID: 33933206.</p>	May 2021	<p>Declare and partial exclusion</p> <p>Participate in discussion of evidence, exclusion from drafting of</p>

Name	Job title and organisation	Type of interest	Description of interest	Relevant dates	Comments
					<p>recommendations on tocilizumab.</p> <p>Specific to recommendations that were published in April 2021 and October 2021.</p>
<p>Dr Lucy Lamb (Member on main and therapeutic subpanel)</p>	<p>Army Consultant Infectious Diseases and General Medicine, Royal Free London/Defence Medical Services</p>	<p>Non-financial professional and personal</p>	<p>European Respiratory Society Monograph on COVID-19 - Chapter of the Clinical Features of COVID-19. Khan N, Lamb L, Moores (going through first external review).</p>	<p>November 2021</p>	<p>Declare and participate</p> <p>Interest will be kept under review depending on matter under consideration.</p> <p>Paper not yet published.</p>
<p>Dr Lucy Lamb (Member on main and therapeutic subpanel)</p>	<p>Army Consultant Infectious Diseases and General Medicine, Royal Free London/Defence Medical Services</p>	<p>Non-financial professional and personal</p>	<p>Aspirin in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial. RECOVERY Collaborative Group.</p> <p>Part of the Clinical group at the Royal Free site, not writing committee. I am listed as one of the site clinicians not a paper author but my name appears on the manuscript in the appendix.</p>	<p>November 2021</p>	<p>Declare and participate</p> <p>Declaration is sufficient mitigation. Therapeutic not under review.</p>
<p>Dr Lucy Lamb (Member on main and therapeutic subpanel)</p>	<p>Army Consultant Infectious Diseases and General Medicine, Royal Free London/Defence Medical Services</p>	<p>Non-financial professional and personal</p>	<p>Publications European Respiratory Society - Chapter on Clinical Features of COVID19 book chapter</p> <p>A 10-fold and greater increase in D-dimer at admission in COVID-19 patients is highly predictive of pulmonary embolism in a retrospective cohort study. Perera A et al. Adv Hematol 2021.</p>	<p>Start 01/2022 End N/A</p>	<p>Declare and participate</p> <p>Interest will be kept under review depending on matter under consideration.</p>
<p>Dr Lucy Lamb (Member on main and therapeutic subpanel)</p>	<p>Army Consultant Infectious Diseases and General Medicine, Royal Free</p>	<p>Non-financial professional and personal</p>	<p>Collaborator with a military study (IMPACT COVID) looking at vitamin D supplementation in recruits and seroprevalance of COVID19 (not yet published). Study is MOD funded to the PI team (Col David Woods).</p>	<p>05/05/2020-ongoing</p>	<p>Declare and participate</p> <p>Interest will be kept under review depending on matter under consideration.</p>

Name	Job title and organisation	Type of interest	Description of interest	Relevant dates	Comments
	London/Defence Medical Services				Interest is non-specific to recommendations published in July 2022.
Dr Paddy McMaster (Member on main and therapeutic subpanel)	Consultant in Paediatric Infectious Diseases, North Manchester General Hospital	Non-financial professional and personal	UK Paediatric Antimicrobial Stewardship (UK-PAS) Network: lead author of Antimicrobial summary for hospitals 30/8/19 UK and Ireland good practice recommendations for improving antimicrobial stewardship and promoting safe ambulation of children presenting with common infections to secondary care hospitals	30 August 2019	Declare and participate. Interest is non-specific
Dr Paddy McMaster (Member on main and therapeutic subpanel)	Consultant in Paediatric Infectious Diseases, North Manchester General Hospital	Non-financial professional and personal	Author of pneumonia and orbital cellulitis pathways	30 August 2019	Declare and participate. Interest is non-specific
Dr Paddy McMaster (Member on main and therapeutic subpanel)	Consultant in Paediatric Infectious Diseases, North Manchester General Hospital	Non-financial professional and personal	Paediatric Hepatitis C Operational Delivery Network steering committee	4 February 2021	Declare and participate. Interest is non-specific
Dr Paddy McMaster (Member on main and therapeutic subpanel)	Consultant in Paediatric Infectious Diseases, North Manchester General Hospital	Non-financial professional and personal	Hepatitis Infection Paediatric Network chair	26 January 2021	Declare and participate. Interest is non-specific
Dr Paddy McMaster (Member on main and therapeutic subpanel)	Consultant in Paediatric Infectious Diseases, North Manchester General Hospital	Non-financial professional and personal	British Association of Sexual Health and HIV – Congenital Syphilis guideline author	29 Sept 2020	Declare and participate. Interest is non-specific
Dr Paddy McMaster (Member on main and therapeutic subpanel)	Consultant in Paediatric Infectious Diseases, North Manchester General Hospital	Non-financial professional and personal	I am part of the National Paediatric COVID-19 Therapeutics Advisory Group which was set up to ensure communication between NHSE, RCPCH, pharmacists, and paediatric infectious diseases. I represent the last group based on managing children	18 December 2021-ongoing	Declare and participate Declaration is sufficient mitigation

Name	Job title and organisation	Type of interest	Description of interest	Relevant dates	Comments
	Manchester General Hospital		with acute COVID. This is an unpaid position which has no official role in policy making but is bringing expert advice together.		
Dr Paddy McMaster (Member on main and therapeutic subpanel)	Consultant in Paediatric Infectious Diseases, North Manchester General Hospital	Non-financial professional and personal	Principal investigator for EPIC-PEDS (Evaluation of Protease Inhibition for COVID-19 in Pediatric Patients). A Phase 2/3 interventional safety, pharmacokinetics, and efficacy, open-label, multi-centre, single-arm study to investigate orally administered PF-07321332 (Nirmatrelvir)/Ritonavir in non-hospitalised symptomatic paediatric participants with COVID-19 who are at risk of progression to severe disease.	17 February 2022-on-going	Declare and partial exclusion. Participate in discussion of evidence but excluded from drafting of associated recommendations on nirmatrelvir / ritonavir (Paxlovid).
Dr Paddy McMaster (Member on main and therapeutic subpanel)	Consultant in Paediatric Infectious Diseases, North Manchester General Hospital	Non-financial professional and personal	Principal Investigator for: Open-label, Uncontrolled, Single dose Study to Evaluate the Pharmacokinetics, Pharmacodynamics, and Safety of AZD7442 in Pediatric Participants Aged \geq 29 Weeks Gestational Age to < 18 Years (Pending approval)	17 February 2022-on-going	Declare and participate Interest will be kept under review depending on matter under consideration. This specific intervention is not currently being considered as part of this guideline.
Stella O'Brien (Member on main and therapeutic subpanel)	Lay member	Non-financial professional and personal	I acted as a lay reviewer for the PRINCIPLE colchicine trial for the BMJ As a reviewer, I have online access to the BMJ as a recognition of my activities as a reviewer.	19 Oct 2021	Declare and participate Declaration is sufficient mitigation
Stella O'Brien (Member on main and therapeutic subpanel)	Lay member	Non-financial professional and personal	I acted as a consumer reviewer for the Cochrane review: 'Inhaled corticosteroids for the treatment of COVID-19'	8 Nov 2021	Declare and participate Declaration is sufficient mitigation
Stella O'Brien (Member on main and therapeutic subpanel)	Lay member	Non-financial professional and personal	I acted as a lay reviewer for "mRNA vaccines effectiveness and waning of protection against SARS-CoV-2 infection and severe COVID-19 during the epidemic phase with predominant circulation of the Delta variant in Italy: a retrospective cohort study" for the BMJ	10 Nov 2021	Declare and participate Declaration is sufficient mitigation

Name	Job title and organisation	Type of interest	Description of interest	Relevant dates	Comments
			As a reviewer, I have online access to the BMJ as a recognition of my activities as a reviewer.		
Stella O'Brien (Member on main and therapeutic subpanel)	Lay member	Direct-financial	<p>ID3808 'Commissioning Support Briefing on remdesivir for COVID-19'.</p> <p>I attended a one-off meeting in relation to this piece of work and received a lay honorarium.</p> <p>This was prepared by NICE on behalf of the Department of Health and Social Care and NHS England. This commissioning support briefing aimed to provide evidence for policy makers but was not NICE guidance or advice.</p> <p>Part of the work has now published: A Cost-Effectiveness Analysis of Remdesivir for the Treatment of Hospitalized Patients With COVID-19 in England and Wales - Value in Health (valueinhealthjournal.com).</p>	March 2021	<p>Declare and participate</p> <p>Declaration is sufficient mitigation. Reimbursement for providing lay advice is reasonable and no opportunity for further financial gain.</p>
Prof Wei Shen Lim (Member on main and therapeutic subpanel)	Consultant Respiratory Physician, Nottingham University Hospitals NHS Trust	Indirect-financial	Wei Shen Lim's institution received unrestricted investigator-initiated research funding from Pfizer for a multi-centre, population based, pneumococcal serotype pneumonia cohort study for which he is the Chief Investigator. This is not related to COVID-19.	April 2020 – present	<p>Declare and participate.</p> <p>Interest is non-specific and employer receives funding</p>
Prof Wei Shen Lim (Member on main and therapeutic subpanel)	Consultant Respiratory Physician, Nottingham University Hospitals NHS Trust	Non-financial professional and personal	Member of the New and Emerging Respiratory Viral Threats Advisory Group (NERVTAG).	2014 – present	<p>Declare and participate.</p> <p>Interest is non-specific</p>
Prof Wei Shen Lim (Member on main and therapeutic subpanel)	Consultant Respiratory Physician, Nottingham University Hospitals NHS Trust	Non-financial professional and personal	Chair, COVID-19 immunisation, Joint Committee on Vaccination and Immunisation (JCVI) to UK health departments	2014 – present	<p>Declare and participate.</p> <p>Interest is non-specific</p>

Name	Job title and organisation	Type of interest	Description of interest	Relevant dates	Comments
Prof Wei Shen Lim (Member on main and therapeutic subpanel)	Consultant Respiratory Physician, Nottingham University Hospitals NHS Trust	Non-financial professional and personal	National lead, British Thoracic Society community acquired pneumonia audit programme	2008 – present	Declare and participate. Interest is non-specific
Prof Wei Shen Lim (Member on main and therapeutic subpanel)	Consultant Respiratory Physician, Nottingham University Hospitals NHS Trust	Non-financial professional and personal and indirect-financial	I am a co-investigator, co-author and on the writing committee for the RECOVERY Trial. This central role applies to trial design and all interventions studied. Funding goes to the University of Oxford.	2021-ongoing	Declare and participate Interest to be kept under review and will participate in discussion of evidence, exclusion from drafting of associated recommendations. Not applicable for respiratory sub panel Trial data included in the evidence base.
Prof Wei Shen Lim (Member on main and therapeutic subpanel)	Consultant Respiratory Physician, Nottingham University Hospitals NHS Trust	Non-financial professional and personal and indirect-financial	CI of the NIHR funded ASAP Trial which was set up to test dexamethasone in pandemic influenza, and which became the Dexamethasone arm of the RECOVERY TRIAL. Funding goes to my employer.	2012-ongoing	Declare and partial exclusion Participate in discussion of evidence, exclusion from drafting of associated recommendations on corticosteroids Specific to recommendations that were published in April 2021.

Name	Job title and organisation	Type of interest	Description of interest	Relevant dates	Comments
					Not applicable for respiratory sub panel
Prof Wei Shen Lim (Member on main and therapeutic subpanel)	Consultant Respiratory Physician, Nottingham University Hospitals NHS Trust	Non-financial professional and personal	Harnden A, Lim WS, Earnshaw A. COVID-19 vaccination programme: a central role for primary care. Br J Gen Pract. 2021 Jan 28;71(703):52-53. COVID-19 vaccination programme: a central role for primary care - PubMed (nih.gov)	2021	Declare and participate. Interest is non-specific
Prof Wei Shen Lim (Member on main and therapeutic subpanel)	Consultant Respiratory Physician, Nottingham University Hospitals NHS Trust	Non-financial professional and personal	RECOVERY Collaborative Group, Horby P*, Lim WS*, Emberson JR, Mafham M, Bell JL, Linsell L, Staplin N, Brightling C, Ustianowski A, Elmahi E, Prudon B, Green C, Felton T, Chadwick D, Rege K, Fegan C, Chappell LC, Faust SN, Jaki T, Jeffery K, Montgomery A, Rowan K, Juszczak E, Baillie JK, Haynes R, Landray MJ. Dexamethasone in Hospitalized Patients with Covid-19 - Preliminary Report. N Engl J Med. 2020 Jul 17 (*joint first authors) Dexamethasone in Hospitalized Patients with Covid-19 - PubMed (nih.gov)	2020	Declare and partial exclusion Participate in discussion of evidence, exclusion from drafting of associated recommendations on corticosteroids. Specific to recommendations that were published in April 2021. Not applicable for respiratory sub panel
Prof Wei Shen Lim (Member on main and therapeutic subpanel)	Consultant Respiratory Physician, Nottingham University Hospitals NHS Trust	Non-financial professional and personal	RECOVERY Collaborative Group. Lopinavir-ritonavir in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial. Lancet. 2020 Oct 5;396(10259):1345-52. Lopinavir-ritonavir in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial - PubMed (nih.gov)	2020	Declare and Participate Interest will be kept under review depending on the matter under consideration. This specific intervention is not currently being considered as part of this guideline.

Name	Job title and organisation	Type of interest	Description of interest	Relevant dates	Comments
Prof Wei Shen Lim (Member on main and therapeutic subpanel)	Consultant Respiratory Physician, Nottingham University Hospitals NHS Trust	Non-financial professional and personal	RECOVERY Collaborative Group, Horby P, Mafham M, Linsell L, Bell JL, Staplin N, Emberson JR, Wiselka M, Ustianowski A, Elmahi E, Prudon B, Whitehouse T, Felton T, Williams J, Faccenda J, Underwood J, Baillie JK, Chappell LC, Faust SN, Jaki T, Jeffery K, Lim WS, Montgomery A, Rowan K, Tarning J, Watson JA, White NJ, Juszczak E, Haynes R, Landray MJ. Effect of Hydroxychloroquine in Hospitalized Patients with Covid-19. N Engl J Med. 2020 Oct 8;NEJMoa2022926. doi: 10.1056/NEJMoa2022926. Effect of Hydroxychloroquine in Hospitalized Patients with Covid-19 - PubMed (nih.gov)	2020	Declare and Participate Interest will be kept under review depending on the matter under consideration. This specific intervention is not currently being considered as part of this guideline.
Prof Wei Shen Lim (Member on main and therapeutic subpanel)	Consultant Respiratory Physician, Nottingham University Hospitals NHS Trust	Non-financial professional and personal	WHO Rapid Evidence Appraisal for COVID-19 Therapies (REACT) Working Group, Sterne JAC, Murthy S, Diaz JV, Slutsky AS, Villar J, Angus DC, Annane D, Azevedo LCP, Berwanger O, Cavalcanti AB, Dequin PF, Du B, Emberson J, Fisher D, Giraudeau B, Gordon AC, Granholm A, Green C, Haynes R, Heming N, Higgins JPT, Horby P, Jüni P, Landray MJ, Le Gouge A, Leclerc M, Lim WS, Machado FR, McArthur C, Meziani F, Møller MH, Perner A, Petersen MW, Savovic J, Tomazini B, Veiga VC, Webb S, Marshall JC. Association Between Administration of Systemic Corticosteroids and Mortality Among Critically Ill Patients With COVID-19: A Meta-analysis. JAMA. 2020 Oct 6;324(13):1330-1341. Association Between Administration of Systemic Corticosteroids and Mortality Among Critically Ill Patients With COVID-19: A Meta-analysis - PubMed (nih.gov)	2020	Declare and partial exclusion Participate in discussion of evidence, exclusion from drafting of associated recommendations on corticosteroids. Specific to recommendations that were published in April 2021. Not applicable for respiratory sub panel
Prof Wei Shen Lim (Member on main and therapeutic subpanel)	Consultant Respiratory Physician, Nottingham University Hospitals NHS Trust	Non-financial professional and personal	Lansbury L, Lim B, Baskaran V, Lim WS. Co-infections in people with COVID-19: a systematic review and meta-analysis. J Infect. 2020 Aug;81(2):266-275. Co-infections in people with COVID-19: a systematic review and meta-analysis - PubMed (nih.gov)	2020	Declare and participate. Declaration is sufficient mitigation.
Prof Wei Shen Lim	Consultant Respiratory Physician,	Non-financial professional and personal	Simpson CR, Thomas BD, Challen K, De Angelis D, Fragaszy E, Goodacre S, Hayward A, Lim WS, Rubin GJ, Semple MG, Knight M; NIHR hibernated pandemic studies collaborative group. The UK	2020	Declare and participate.

Name	Job title and organisation	Type of interest	Description of interest	Relevant dates	Comments
(Member on main and therapeutic subpanel)	Nottingham University Hospitals NHS Trust		hibernated pandemic influenza research portfolio: triggered for COVID-19. Lancet Infect Dis. 2020 Jul;20(7):767-769. The UK hibernated pandemic influenza research portfolio: triggered for COVID-19 - PubMed (nih.gov)		Interest is non-specific
Prof Wei Shen Lim (Member on main and therapeutic subpanel)	Consultant Respiratory Physician, Nottingham University Hospitals NHS Trust	Non-financial professional and personal	Roberts CM, Levi M, McKee M, Schilling R, Lim WS, Grocott MPW. COVID-19: a complex multisystem disorder. Br J Anaesth. 2020 Jun 20:S0007-0912(20)30459-1. COVID-19: a complex multisystem disorder - PubMed (nih.gov)	2020	Declare and participate. Declaration is sufficient mitigation
Prof Wei Shen Lim (Member on main and therapeutic subpanel)	Consultant Respiratory Physician, Nottingham University Hospitals NHS Trust	Direct-financial	Horby PW, Campbell M, Staplin N, Spata E, Emberson JR, Pessoa-Amorim G, Peto L, Brightling CE, Sarkar R, Thomas K, Jeebun V, Ashish A, Tully R, Chadwick D, Sharafat M, Stewart R, Rudran B, Baillie JK, Buch MH, Chappell LC, Day JN, Furst SN, Jaki T, Jeffery K, Juszczak E, Lim WS, Montgomery A, Mumford A, Rowan K, Thwaites G, Mafham M, Haynes R, Landray MJ : Tocilizumab in patients admitted to hospital with COVID-19 (RECOVERY): preliminary results of a randomised, controlled, open-label, platform trial. medRxiv 2021; 2021021121249258 Tocilizumab in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial - PMC (nih.gov)	2021	Declare and partial exclusion Participate in discussion of evidence, exclusion from drafting of recommendations on tocilizumab. Specific to the recommendations that were published in April 2021 and October 2021. Not applicable for respiratory sub panel
Prof Wei Shen Lim (Member on main and therapeutic subpanel)	Consultant Respiratory Physician, Nottingham University Hospitals NHS Trust	Direct-financial	RESEARCH GRANT: 2020 NIHR HTA (£1,726,187). PROphylactic TrEatment of COVID in Care Homes Trial (PROTECT-CH). Co-applicant.	2020	Declare and participate Interest will be kept under review depending on matter under consideration Study has not yet started.
Prof Wei Shen Lim (Member on main and therapeutic subpanel)	Consultant Respiratory Physician, Nottingham University	Non-financial professional and personal and indirect-financial	I am a member of the National Clinical Policy, Specialised commissioning group that discussed Remdesivir and Tocilizumab.	2021-ongoing	Declare and participate. Declaration is sufficient mitigation.

Name	Job title and organisation	Type of interest	Description of interest	Relevant dates	Comments
	Hospitals NHS Trust				
Prof Wei Shen Lim (Member on main and therapeutic subpanel)	Consultant Respiratory Physician, Nottingham University Hospitals NHS Trust	Non-financial professional and personal	<p>Azithromycin in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial. RECOVERY Collaborative Group. Lancet. 2021 Feb 13;397(10274):605-612. doi: 10.1016/S0140-6736(21)00149-5. Epub 2021 Feb 2. PMID: 33545096</p> <p>Azithromycin in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial - PubMed (nih.gov)</p>	2021	<p>Declare and partial exclusion.</p> <p>Participate in discussion of evidence, exclusion from drafting of recommendations on azithromycin.</p> <p>Specific to the recommendations that were published in June 2021.</p> <p>Not applicable for respiratory sub panel</p>
Prof Wei Shen Lim (Member on main and therapeutic subpanel)	Consultant Respiratory Physician, Nottingham University Hospitals NHS Trust	Non-financial professional and personal	<p>Manuscript number: JMM-D-20-00714R2</p> <p>Title: Co-infection in critically ill patients with COVID-19 An observational cohort study from England</p> <p>Authors: Vadsala Baskaran; Hannah Lawrence; Louise E Lansbury; Karmel Webb; Shahideh Safavi; Izzah Zainuddin; Tausif Huq; Charlotte Eggleston; Jayne Ellis; Clare Thakker; Bethan Charles; Sara Boyd; Tom Williams; Claire Phillips; Ethan Redmore; Sarah Platt; Eve Hamilton; Andrew Barr; Lucy Venyo; Peter Wilson; Tom Bewick; Priya Daniel; Paul Dark; Adam R Jeans; Jamie McCanny; Jonathan D Edgeworth; Martin J Llewelyn; Matthias L Schmid; Tricia M McKeever; Martin Beed; Wei Shen Lim</p> <p>Co-infection in critically ill patients with COVID-19: an observational cohort study from England - PubMed (nih.gov)</p>	2021	<p>Declare and participate</p> <p>Interest is non-specific.</p>
Prof Wei Shen Lim (Member on main and therapeutic subpanel)	Consultant Respiratory Physician, Nottingham University	Non-financial professional and personal	<p>Convalescent plasma in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial</p>	2021	<p>Declare and participate</p> <p>Interest will be kept under review depending</p>

Name	Job title and organisation	Type of interest	Description of interest	Relevant dates	Comments
	Hospitals NHS Trust		The RECOVERY Collaborative Group, Peter W Horby, Lise Estcourt, Leon Peto, Jonathan R Emberson, Natalie Staplin, Enti Spata, Guilherme Pessoa-Amorim, Mark Campbell, Alistair Roddick, Nigel E Brunskill, Tina George, Daniel Zehnder, Simon Tiberi, Ni Ni Aung, Alison Uriel, John Widdrington, George Koshy, Thomas Brown, Steven Scott, J Kenneth Baillie, Maya H Buch, Lucy C Chappell, Jeremy N Day, Saul N Faust, Thomas Jaki, Katie Jeffery, Edmund Juszczak, Wei Shen Lim , Alan Montgomery, Andrew Mumford, Kathryn Rowan, Guy Thwaites, Marion Mafham, David Roberts, Richard Haynes, Martin J Landray medRxiv 2021.03.09.21252736; doi: https://doi.org/10.1101/2021.03.09.21252736		on the matter under consideration. This specific intervention is not currently being considered as part of this guideline.
Prof Wei Shen Lim (Member on main and therapeutic subpanel)	Consultant Respiratory Physician, Nottingham University Hospitals NHS Trust	Non-financial professional and personal	Colchicine in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial RECOVERY Collaborative Group, Peter W Horby, Mark Campbell, Enti Spata, Jonathan R Emberson, Natalie Staplin, Guilherme Pessoa-Amorim, Leon Peto, Martin Wiselka, Laura Wiffen, Simon Tiberi, Ben Caplin, Caroline Wroe, Christopher Green, Paul Hine, Benjamin Prudon, Tina George, Andrew Wight, J Kenneth Baillie, Buddha Basnyat, Maya H Buch, Lucy C Chappell, Jeremy N Day, Saul N Faust, Raphael Hamers, Thomas Jaki, Edmund Juszczak, Katie Jeffery, Wei Shen Lim, Alan Montgomery, Andrew Mumford, Kathryn Rowan, Guy Thwaites, Marion Mafham, Richard Haynes, Martin J Landray medRxiv 2021.05.18.21257267; doi: https://doi.org/10.1101/2021.05.18.21257267	2021	Declare and partial exclusion Participate in discussion of evidence, exclusion from drafting of recommendations for Colchicine. Specific to the recommendations that were published in November 2021.
Prof Peter Wilson (Member on main and therapeutic subpanel until May 2022)	Consultant Microbiologist, University College London Hospitals	Direct, financial	Roche Drug Safety Monitoring Board for biologics trials. Only advised on trials of a few biologics and all related to treatment of rheumatoid or inflammatory conditions not infective (no dealings with Tocilizumab).	2014 – ongoing	Declare and participate. Interest is non-specific
Prof Peter Wilson (Member on main and therapeutic	Consultant Microbiologist, University	Direct, financial	Pfizer advisory board on new antibiotics 2019 ceased 2020	2019 - 2020	Declare and participate.

Name	Job title and organisation	Type of interest	Description of interest	Relevant dates	Comments
subpanel until May 2022)	College London Hospitals				Declaration is sufficient mitigation. This interest has ceased.

Expert advisory therapeutic subpanel members

Name	Job title and organisation	Type of interest	Description of interest	Relevant dates	Comments
Prof Alison Eastwood (Member on therapeutic subpanel)	Professor of Research, Centre for Reviews and Dissemination, University of York	Direct, financial	I am a member of one of the independent academic teams (at the Centre for Reviews and Dissemination, University of York) commissioned by NICE (through the National Institute for Health Research) to undertake technology assessment reviews.	2009 – ongoing	Declare and participate. Interest is non-specific
Prof Alison Eastwood (Member on therapeutic subpanel)	Professor of Research, Centre for Reviews and Dissemination, University of York	Indirect	Members of staff at the Centre for Reviews and Dissemination, University of York are involved in an ongoing project commissioned by the NIHR Policy Research Programme Reviews Facility: Covid-19: a living systematic map of the evidence	March 2020 – ongoing	Declare and participate. Interest is non-specific
Dr Karen Kirkham (Member on therapeutic subpanel until July 2021)	Clinical Advisor Systems Development and Population Health Management, NHS England & Improvement	N/A	None	February 2021	Declare and participate.
Marisa Lanzman (Member on therapeutic subpanel from October 2021)	Senior Pharmacist – Infection and ITU, Royal Free London NHS Foundation Trust	Non-financial professional and personal	Claire Y Mason, Tanmay Kanitkar, Charlotte J Richardson, Marisa Lanzman, Zak Stone, Tabitha Mahungu, Damien Mack, Emmanuel Q Wey, Lucy Lamb, Indran Balakrishnan, Gabriele Pollara, Exclusion of bacterial co-infection in COVID-19 using baseline inflammatory markers and their response to antibiotics, Journal of Antimicrobial Chemotherapy, Volume 76, Issue 5, May 2021, Pages 1323–1331	May 2021	Declare and participate Interest is specific and declaration is sufficient mitigation and will be kept under review
Marisa Lanzman (Member on therapeutic subpanel from October 2021)	Senior Pharmacist – Infection and ITU, Royal Free	Non-financial professional and personal	Ashiru-Oredope, D.; Kerr, F.; Hughes, S.; Urch, J.; Lanzman, M.; Yau, T.; Cockburn, A.; Patel, R.; Sheikh, A.; Gormley, C.; Chavda, A.; Vaghela, T.; Phillips, C.; Reid, N.; Brady, A. Assessing the Impact of COVID-19 on Antimicrobial Stewardship Activities/Programs in the United Kingdom. Antibiotics 2021	2021	Declare and participate Interest is specific and declaration is sufficient

Name	Job title and organisation	Type of interest	Description of interest	Relevant dates	Comments
	London NHS Foundation Trust				mitigation and will be kept under review
Marisa Lanzman (Member on therapeutic subpanel from October 2021)	Senior Pharmacist – Infection and ITU, Royal Free London NHS Foundation Trust	Non-financial professional and personal	Wey EQ, Bristow C, Nandani A, O'Farrell B, Pang J, Lanzman M, Yang S, Ho S, Mack D, Spiro M, Balakrishnan I, Bhagani S, Pollara G. Preserved C-reactive protein responses to blood stream infections following tocilizumab treatment for COVID-19. J Infect. 2021 Aug 14:S0163-4453	August 2021	Declare and participate Interest is specific and declaration is sufficient mitigation and will be kept under review Member was not on panel for recommendations on Tocilizumab.
Dr Tessa Lewis (Member on therapeutic subpanel from July 2021)	GP & Medical Adviser, Aneurin Bevan University Health Board	Direct Financial	Medical adviser to PHE primary care interventions unit/TARGET toolkit. Sessional work involved the support and development of resources to support antimicrobial stewardship.	September 2019 – ongoing	Declare and participate. Interest is non-specific
Dr Tessa Lewis (Member on therapeutic subpanel from July 2021)	GP & Medical Adviser, Aneurin Bevan University Health Board	Direct Financial	Development of webinar, slide set and delivery of two teaching sessions: "Common Infections in extraordinary times, decision points for remote management. Sessional work for PHE/TARGET.	2020	Declare and participate Interest is specific and declaration is sufficient mitigation and will be kept under review
Dr Tessa Lewis (Member on therapeutic subpanel from July 2021)	GP & Medical Adviser, Aneurin Bevan University Health Board	Direct Financial	Development of an e-learning module on the management of urinary tract infections - funded by HEE/eLfh	2020	Declare and participate. Interest is non-specific
Dr Tessa Lewis (Member on therapeutic subpanel from July 2021)	GP & Medical Adviser, Aneurin Bevan University Health Board	Non-financial professional and personal	NICE COVID-19 rapid guideline: community acquired pneumonia update - member	2019	Declare and participate. Interest is non-specific
Dr Tessa Lewis (Member on therapeutic)	GP & Medical Adviser, Aneurin Bevan University Health Board	Non-financial professional and personal	Chair of NICE COVID-19 rapid guideline: delivery of systemic anticancer treatments	2020	Declare and participate. Interest is non-specific

Name	Job title and organisation	Type of interest	Description of interest	Relevant dates	Comments
subpanel from July 2021)					
Prof Andrew Owen (Member on therapeutic subpanel from March 2022)	Professor of Pharmacology, University of Liverpool	Direct, financial	<p>Director of Tandem Nano Ltd. Work conducted at Tandem Nano Ltd and/or the University of Liverpool seeks to develop new formulations of drugs to enable different routes of administration. For COVID19, this work has focused on drugs which were originally developed for other diseases but for which data now exist to suggest putative utility in COVID19, either through antiviral activity or through overlap in the pathology with the original indication. The hope is that these formulations may improve the likelihood of demonstrable efficacy of these drugs in COVID19 over and above direct repurposing of the products currently available.</p> <p>If any overlap arises between drugs being reformulated and the medicines being assessed in NG191 this will be immediately declared.</p>	Ongoing	<p>Declare and participate.</p> <p>Interest is not directly related to casirivimab and imdevimab recommendations reviewed in March 2022.</p> <p>Interest is non-specific to baricitinib recommendations published in May 2022.</p> <p>Interest will be kept under review depending on matter under consideration.</p>
Prof Andrew Owen (Member on therapeutic subpanel from March 2022)	Professor of Pharmacology, University of Liverpool	Direct, financial	<p>Tandem Nano Ltd. has received funding for research and development from Gilead</p> <p>Gilead funding is unrelated to COVID19.</p>	Aug 2021	<p>Declare and participate</p> <p>Interest is non-specific to remdesivir recommendations published in July 2022</p>
Prof Andrew Owen (Member on therapeutic subpanel from March 2022)	Professor of Pharmacology, University of Liverpool	Direct, financial	<p>Tandem Nano Ltd. has received funding for research and development</p> <p>BerGenBio funding is partially related to COVID19</p>	June 2022	<p>Declare and participate</p> <p>Interest is non-specific to recommendations published to date.</p> <p>Interest will be kept under review depending on matter under consideration.</p>

Name	Job title and organisation	Type of interest	Description of interest	Relevant dates	Comments
Prof Andrew Owen (Member on therapeutic subpanel from March 2022)	Professor of Pharmacology, University of Liverpool	Non-financial professional and personal	Co-inventor of multiple patents relating to drug delivery including for reformulations of approved drugs being repurposed for COVID19. These are all filed by University of Liverpool and some of these patents have been licensed to Tandem Nano Ltd. I don't hold any patents personally.	Ongoing	Declare and participate Interest is non-specific to recommendations published to date. Interest will be kept under review depending on matter under consideration.
Prof Andrew Owen (Member on therapeutic subpanel from March 2022)	Professor of Pharmacology, University of Liverpool	Non-Financial professional and personal	Member of the Trial Management Group for the UK National phase I/II COVID19 platform trial, AGILE. Ridgeback and GlaxoSmithKline have provided funding to the AGILE phase I/II platform to evaluate SARS-CoV-2 candidates. I am not an applicant for the funding. Monoclonal antibody developed by GSK/Vir under evaluation in AGILE (not sotrovimab) I am not an applicant for the funding.	Ongoing	Declare and participate Interest is not directly related to casirivimab and imdevimab recommendations reviewed in March 2022 Interest will be kept under review depending on matter under consideration
Prof Andrew Owen (Member on therapeutic subpanel from March 2022)	Professor of Pharmacology, University of Liverpool	Indirect	The University of Liverpool received research funding from ViiV, Merck, and Janssen relating to development of formulations or pharmacology understanding of drugs used in non-COVID19 research (predominantly HIV).	2019	Declare and participate Interest is non- specific to matter under review
Prof Andrew Owen (Member on therapeutic subpanel from March 2022)	Professor of Pharmacology, University of Liverpool	Direct Financial	Received consultancy from Gilead, ViiV and Merck relating to pharmacology of HIV drugs and not related to COVID19	2019	Declare and participate Interest is non- specific to matter under review
Prof Andrew Owen (Member on therapeutic subpanel from March 2022)	Professor of Pharmacology, University of Liverpool	Indirect	Has received research funding from early-stage start-up companies for evaluation of novel SARS-CoV-2 antiviral medicines	ongoing	Declare and participate

Name	Job title and organisation	Type of interest	Description of interest	Relevant dates	Comments
					Interest will be kept under review depending on matter under consideration
Prof Andrew Owen (Member on therapeutic subpanel from March 2022)	Professor of Pharmacology, University of Liverpool	Non-Financial professional and personal	Academic publication in pre print: Lack of Ronapreve REGN-CoV casirivimab and imdevimab virological efficacy against the SARS-CoV 2 Omicron variant B11529 in K18-hACE2 mice Lee Tatham, Joanne Sharp, Edyta Kijak, Joanne Herriott, Megan Neary, Helen Box, Anthony Valentijn, Helen Cox, Henry Pertinez, Paul Curley, Usman Arshad, Rajith Kr Rajoli, Steve Rannard, James Stewart, Andrew Owen	2022	Declare and participate Interest is specific but was not included in the evidence base for neutralising monoclonal antibodies due to study type. The content was not deemed to prejudice the panel member from approaching the evidence objectively.
Prof Andrew Owen (Member on therapeutic subpanel from March 2022)	Professor of Pharmacology, University of Liverpool	Non-Financial professional and personal	Adeola, Fowotade & Bamidele, Folasade & Egbetola, Boluwatife & Adefuye, Bolanle & Fagbamigbe, Adeniyi & Adeagbo, Babatunde & Olagunoye, Ajibola & Ojo, Temitope & Adebisi, Akindele & Olagunju, Omobolanle & Ladipo, Olabode & Akinloye, Abdulafeez & Onayade, Adedeji & Bolaji, Oluseye & Happi, Christian & Rannard, Steven & Owen, Andrew & Olagunju, Adeniyi. (2022). Efficacy and safety of nitazoxanide combined with ritonavir-boosted atazanavir for the treatment of mild to moderate COVID-19 . 10.1101/2022.02.03.22270152.	February 2022	Declare and participate Interest will be kept under review depending on the matter under consideration. This specific intervention is not currently being considered as part of this guideline.
Prof Andrew Owen (Member on therapeutic subpanel from March 2022)	Professor of Pharmacology, University of Liverpool	Non-Financial professional and personal	Olagunju, Adeniyi & Adeola, Fowotade & Olagunoye, Ajibola & Ojo, Temitope & Adefuye, Bolanle & Fagbamigbe, Adeniyi & Adebisi, Akindele & Olagunju, Omobolanle & Ladipo, Olabode & Akinloye, Abdulafeez & Adeagbo, Babatunde & Onayade, Adedeji & Bolaji, Oluseye & Happi, Christian & Rannard, Steven & Owen, Andrew. (2021). Efficacy and safety of nitazoxanide plus atazanavir/ritonavir for the treatment of moderate to severe	December 2021	Declare and participate Interest will be kept under review depending on the matter under consideration.

Name	Job title and organisation	Type of interest	Description of interest	Relevant dates	Comments
			COVID-19 (NACOVID): A structured summary of a study protocol for a randomised controlled trial. <i>Trials</i> . 22. 10.1186/s13063-020-04987-8.		This specific intervention is not currently being considered as part of this guideline.
Prof Andrew Owen (Member on therapeutic subpanel from March 2022)	Professor of Pharmacology, University of Liverpool	Non-Financial professional and personal	Elkateb, Heba & Tatham, Lee & Cauldbeck, Helen & Niezabitowska, Edyta & Owen, Andrew & Rannard, Steven & McDonald, Tom. (2020). Optimization of the Synthetic Parameters of Lipid Polymer Hybrid Nanoparticles Dual Loaded with Darunavir and Ritonavir for the Treatment of HIV. <i>International Journal of Pharmaceutics</i> . 588. 119794. 10.1016/j.ijpharm.2020.119794.	August 2020	Declare and participate. Interest is non-specific
Prof Andrew Owen (Member on therapeutic subpanel from March 2022)	Professor of Pharmacology, University of Liverpool	Non-Financial professional and personal	Dickinson, Laura & Gurjar, Rohan & Stöhr, Wolfgang & Bonora, Stefano & Owen, Andrew & D'Avolio, Antonio & Cursley, Adam & Molina, Jean-Michel & Fäetkenheuer, Gerd & Vandekerckhove, Linos & Di Perri, Giovanni & Pozniak, Anton & Richert, Laura & Raffi, François & Boffito, Marta. (2019). Population pharmacokinetics and pharmacogenetics of ritonavir-boosted darunavir in the presence of raltegravir or tenofovir disoproxil fumarate/emtricitabine in HIV-infected adults and the relationship with virological response: a sub-study of the NEAT001/ANRS143 randomized trial. <i>The Journal of antimicrobial chemotherapy</i> . 75. 10.1093/jac/dkz479.	November 2019	Declare and participate. Interest is non-specific
Prof Andrew Owen (Member on therapeutic subpanel from March 2022)	Professor of Pharmacology, University of Liverpool	Non-Financial professional and personal	Drug delivery systems as immunomodulators for therapy of infectious disease: Relevance to COVID-19. Brain D, Plant-Hately A, Heaton B, Arshad U, David C, Hedrich C, Owen A, Liptrott NJ. <i>Adv Drug Deliv Rev</i> . 2021 Nov;178:113848. doi: 10.1016/j.addr.2021.113848. Epub 2021 Jun 25. PMID: 34182016 Free PMC article. Review.	June 2021	Declare and participate. Interest is non-specific
Prof Andrew Owen (Member on therapeutic subpanel from March 2022)	Professor of Pharmacology, University of Liverpool	Non-Financial professional and personal	Shutting the gate before the horse has bolted: is it time for a conversation about SARS-CoV-2 and antiviral drug resistance? Hiscox JA, Khoo SH, Stewart JP, Owen A. <i>J Antimicrob Chemother</i> . 2021 Aug 12;76(9):2230-2233. doi: 10.1093/jac/dkab189. PMID: 34142123 Review.	August 2021	Declare and participate. Interest is non-specific

Name	Job title and organisation	Type of interest	Description of interest	Relevant dates	Comments
Prof Andrew Owen (Member on therapeutic subpanel from March 2022)	Professor of Pharmacology, University of Liverpool	Non-Financial professional and personal	Therapeutic Potential of Nitazoxanide: An Appropriate Choice for Repurposing versus SARS-CoV-2? Stachulski AV, Taujanskas J, Pate SL, Rajoli RKR, Aljayyousi G, Pennington SH, Ward SA, Hong WD, Biagini GA, Owen A, Nixon GL, Leung SC, O'Neill PM. ACS Infect Dis. 2021 Jun 11;7(6):1317-1331. doi: 10.1021/acsinfecdis.0c00478. Epub 2020 Dec 22. PMID: 33352056 Free PMC article. Review.	December 2020	Declare and participate Interest will be kept under review depending on the matter under consideration. This specific intervention is not currently being considered as part of this guideline.
Prof Andrew Owen (Member on therapeutic subpanel from March 2022)	Professor of Pharmacology, University of Liverpool	Non-Financial professional and personal	Toward Consensus on Correct Interpretation of Protein Binding in Plasma and Other Biological Matrices for COVID-19 Therapeutic Development. Boffito M, Back DJ, Flexner C, Sjö P, Blaschke TF, Horby PW, Cattaneo D, Acosta EP, Anderson P, Owen A. Clin Pharmacol Ther. 2021 Jul;110(1):64-68. doi: 10.1002/cpt.2099. Epub 2020 Nov 21. PMID: 33113246 Free PMC article. Review.	November 2021	Declare and participate. Interest is non-specific
Prof Andrew Owen (Member on therapeutic subpanel from March 2022)	Professor of Pharmacology, University of Liverpool	Non-Financial professional and personal	Safety perspectives on presently considered drugs for the treatment of COVID-19. Penman SL, Kiy RT, Jensen RL, Beoku-Betts C, Alfirevic A, Back D, Khoo SH, Owen A, Pirmohamed M, Park BK, Meng X, Goldring CE, Chadwick AE. Br J Pharmacol. 2020 Oct;177(19):4353-4374. doi: 10.1111/bph.15204. Epub 2020 Aug 13. PMID: 32681537 Free PMC article. Review.	August 2020	Declare and participate. Open declaration is sufficient mitigation. Non-specific opinion piece. The content was not deemed to prejudice the panel member from approaching the evidence objectively.
Prof Andrew Owen (Member on therapeutic subpanel from March 2022)	Professor of Pharmacology, University of Liverpool	Non-Financial professional and personal	Prioritization of Anti-SARS-Cov-2 Drug Repurposing Opportunities Based on Plasma and Target Site Concentrations Derived from their Established Human Pharmacokinetics. Arshad U, Pertinez H, Box H, Tatham L, Rajoli RKR, Curley P, Neary M, Sharp J, Liptrott NJ, Valentijn A, David C, Rannard SP, O'Neill PM, Aljayyousi G, Pennington SH, Ward SA, Hill A, Back DJ, Khoo SH, Bray PG, Biagini GA, Owen A.	June 2020	Declare and participate. Interest is non-specific

Name	Job title and organisation	Type of interest	Description of interest	Relevant dates	Comments
			Clin Pharmacol Ther. 2020 Oct;108(4):775-790. doi: 10.1002/cpt.1909. Epub 2020 Jun 14. PMID: 32438446 Free PMC article. Review.		
Prof Andrew Owen (Member on therapeutic subpanel from March 2022)	Professor of Pharmacology, University of Liverpool	Non-Financial professional and personal	Unlike Chloroquine, Mefloquine Inhibits SARS-CoV-2 Infection in Physiologically Relevant Cells. Sacramento CQ, Fintelman-Rodrigues N, Dias SSG, Temerozo JR, Da Silva APD, da Silva CS, Blanco C, Ferreira AC, Mattos M, Soares VC, Pereira-Dutra F, Miranda MD, Barreto-Vieira DF, da Silva MAN, Santos SS, Torres M, Chaves OA, Rajoli RKR, Paccanaro A, Owen A, Bou-Habib DC, Bozza PT, Souza TML. Viruses. 2022 Feb 11;14(2):374. doi: 10.3390/v14020374. PMID: 35215969 Free PMC article.	February 2022	Declare and participate Interest will be kept under review depending on the matter under consideration. This specific intervention is not currently being considered as part of this guideline.
Prof Andrew Owen (Member on therapeutic subpanel from March 2022)	Professor of Pharmacology, University of Liverpool	Non-Financial professional and personal	Randomised controlled trial of intravenous nafamostat mesylate in COVID pneumonitis: Phase 1b/2a experimental study to investigate safety, Pharmacokinetics and Pharmacodynamics. Quinn TM, Gaughan EE, Bruce A, Antonelli J, O'Connor R, Li F, McNamara S, Koch O, MacKintosh C, Dockrell D, Walsh T, Blyth KG, Church C, Schwarze J, Boz C, Valanciute A, Burgess M, Emanuel P, Mills B, Rinaldi G, Hardisty G, Mills R, Findlay EG, Jabbal S, Duncan A, Plant S, Marshall ADL, Young I, Russell K, Scholefield E, Nimmo AF, Nazarov IB, Churchill GC, McCullagh JSO, Ebrahimi KH, Ferrett C, Templeton K, Rannard S, Owen A, Moore A, Finlayson K, Shankar-Hari M, Norrie J, Parker RA, Akram AR, Anthony DC, Dear JW, Hirani N, Dhaliwal K. EBioMedicine. 2022 Feb;76:103856. doi: 10.1016/j.ebiom.2022.103856. Epub 2022 Feb 11. PMID: 35152152 Free PMC article. Clinical Trial.	February 2022	Declare and participate Interest will be kept under review depending on the matter under consideration. This specific intervention is not currently being considered as part of this guideline.
Prof Andrew Owen (Member on therapeutic subpanel from March 2022)	Professor of Pharmacology, University of Liverpool	Non-Financial professional and personal	Remdesivir-ivermectin combination displays synergistic interaction with improved in vitro activity against SARS-CoV-2. Jeffreys LN, Pennington SH, Duggan J, Caygill CH, Lopeman RC, Breen AF, Jinks JB, Ardrey A, Donnellan S, Patterson EI, Hughes GL, Hong DW, O'Neill PM, Aljayyousi G, Owen A, Ward SA, Biagini GA. Int J Antimicrob Agents. 2022 Jan 31;59(3):106542. doi: 10.1016/j.ijantimicag.2022.106542. Online ahead of print. PMID: 35093538 Free PMC article.	January 2022	Declare and participate Interest is specific but was not included in the evidence base due to study type.

Name	Job title and organisation	Type of interest	Description of interest	Relevant dates	Comments
					The content was not deemed to prejudice the panel member from approaching the evidence objectively.
Prof Andrew Owen (Member on therapeutic subpanel from March 2022)	Professor of Pharmacology, University of Liverpool	Non-Financial professional and personal	Death following pulmonary complications of surgery before and during the SARS-CoV-2 pandemic. STARSurg Collaborative and COVIDSurg Collaborative. Br J Surg. 2021 Dec 1;108(12):1448-1464. doi: 10.1093/bjs/znab336. PMID: 34871379	December 2021	Declare and participate Interest is non-specific
Prof Andrew Owen (Member on therapeutic subpanel from March 2022)	Professor of Pharmacology, University of Liverpool	Non-Financial professional and personal	An Open Label, Adaptive, Phase 1 Trial of High-Dose Oral Nitazoxanide in Healthy Volunteers: An Antiviral Candidate for SARS-CoV-2. Walker LE, FitzGerald R, Saunders G, Lyon R, Fisher M, Martin K, Eberhart I, Woods C, Ewings S, Hale C, Rajoli RKR, Else L, Dilly-Penchala S, Amara A, Laloo DG, Jacobs M, Pertinez H, Hatchard P, Waugh R, Lawrence M, Johnson L, Fines K, Reynolds H, Rowland T, Crook R, Okenyi E, Byrne K, Mozgunov P, Jaki T, Khoo S, Owen A, Griffiths G, Fletcher TE; AGILE platform. Clin Pharmacol Ther. 2022 Mar;111(3):585-594. doi: 10.1002/cpt.2463. Epub 2021 Nov 13. PMID: 34699618 Free PMC article. Clinical Trial.	November 2021	Declare and participate Interest is non-specific
Prof Andrew Owen (Member on therapeutic subpanel from March 2022)	Professor of Pharmacology, University of Liverpool	Non-Financial professional and personal	A potent SARS-CoV-2 neutralising nanobody shows therapeutic efficacy in the Syrian golden hamster model of COVID-19. Huo J, Mikolajek H, Le Bas A, Clark JJ, Sharma P, Kipar A, Dormon J, Norman C, Weckener M, Clare DK, Harrison PJ, Tree JA, Buttigieg KR, Salguero FJ, Watson R, Knott D, Carnell O, Ngabo D, Elmore MJ, Fotheringham S, Harding A, Moynié L, Ward PN, Dumoux M, Prince T, Hall Y, Hiscox JA, Owen A, James W, Carroll MW, Stewart JP, Naismith JH, Owens RJ. Nat Commun. 2021 Sep 22;12(1):5469. doi: 10.1038/s41467-021-25480-z. PMID: 34552091 Free PMC article.	September 2021	Declare and participate Interest will be kept under review depending on the matter under consideration. This specific intervention is not currently being considered as part of this guideline.
Prof Andrew Owen (Member on therapeutic subpanel from March 2022)	Professor of Pharmacology, University of Liverpool	Non-Financial professional and personal	Optimal dose and safety of molnupiravir in patients with early SARS-CoV-2: a Phase I, open-label, dose-escalating, randomized controlled study.	November 2021	Declare and participate Interest is specific but was not included in the

Name	Job title and organisation	Type of interest	Description of interest	Relevant dates	Comments
subpanel from March 2022)			Khoo SH, Fitzgerald R, Fletcher T, Ewings S, Jaki T, Lyon R, Downs N, Walker L, Tansley-Hancock O, Greenhalf W, Woods C, Reynolds H, Marwood E, Mozgunov P, Adams E, Bullock K, Holman W, Bula MD, Gibney JL, Saunders G, Corkhill A, Hale C, Thorne K, Chiong J, Condie S, Pertinez H, Painter W, Wrixon E, Johnson L, Yeats S, Mallard K, Radford M, Fines K, Shaw V, Owen A, Laloo DG, Jacobs M, Griffiths G. J Antimicrob Chemother. 2021 Nov 12;76(12):3286-3295. doi: 10.1093/jac/dkab318. PMID: 34450619 Free PMC article. Clinical Trial.		evidence base due to study type. The content was not deemed to prejudice the panel member from approaching the evidence objectively.
Prof Andrew Owen (Member on therapeutic subpanel from March 2022)	Professor of Pharmacology, University of Liverpool	Non-Financial professional and personal	Single-dose immunisation with a multimerised SARS-CoV-2 receptor binding domain (RBD) induces an enhanced and protective response in mice. Salzer R, Clark JJ, Vaysburd M, Chang VT, Albecka A, Kiss L, Sharma P, Gonzalez Llamazares A, Kipar A, Hiscox JA, Owen A, Aricescu AR, Stewart JP, James LC, Löwe J. FEBS Lett. 2021 Sep;595(18):2323-2340. doi: 10.1002/1873-3468.14171. Epub 2021 Aug 22. PMID: 34331769 Free PMC article.	August 2021	Declare and participate Interest will be kept under review depending on the matter under consideration. This specific intervention is not currently being considered as part of this guideline.
Prof Andrew Owen (Member on therapeutic subpanel from March 2022)	Professor of Pharmacology, University of Liverpool	Non-Financial professional and personal	AGILE: a seamless phase I/IIa platform for the rapid evaluation of candidates for COVID-19 treatment: an update to the structured summary of a study protocol for a randomised platform trial letter. Griffiths GO, Fitzgerald R, Jaki T, Corkhill A, Reynolds H, Ewings S, Condie S, Tilt E, Johnson L, Radford M, Simpson C, Saunders G, Yeats S, Mozgunov P, Tansley-Hancock O, Martin K, Downs N, Eberhart I, Martin JWB, Goncalves C, Song A, Fletcher T, Byrne K, Laloo DG, Owen A, Jacobs M, Walker L, Lyon R, Woods C, Gibney J, Chiong J, Chandiwana N, Jacob S, Lamorde M, Orrell C, Pirmohamed M, Khoo S; AGILE investigators. Trials. 2021 Jul 26;22(1):487. doi: 10.1186/s13063-021-05458-4. PMID: 34311777 Free PMC article.	July 2021	Declare and participate Interest is non-specific
Prof Andrew Owen (Member on therapeutic	Professor of Pharmacology, University of Liverpool	Non-Financial professional and personal	Evaluation of intranasal nafamostat or camostat for SARS-CoV-2 chemoprophylaxis in Syrian golden hamsters. Neary M, Box H, Sharp J, Tatham L, Curley P, Herriott J, Kijak E, Arshad U, Hobson JJ, Rajoli R, Pertinez H, Valentijn A,	July 2021 July 2021	Declare and participate

Name	Job title and organisation	Type of interest	Description of interest	Relevant dates	Comments
subpanel from March 2022)			Dhaliwal K, McCaughan F, Rannard SP, Kipar A, Stewart JP, Owen A. bioRxiv. 2021 Jul 8:2021.07.08.451654. doi: 10.1101/2021.07.08.451654. Preprint. PMID: 34268511 Free PMC article.		Interest will be kept under review depending on the matter under consideration. This specific intervention is not currently being considered as part of this guideline.
Prof Andrew Owen (Member on therapeutic subpanel from March 2022)	Professor of Pharmacology, University of Liverpool	Non-Financial professional and personal	Pharmacokinetic modelling to estimate intracellular favipiravir ribofuranosyl-5'-triphosphate exposure to support posology for SARS-CoV-2. Pertinez H, Rajoli RKR, Khoo SH, Owen A. J Antimicrob Chemother. 2021 Jul 15;76(8):2121-2128. doi: 10.1093/jac/dkab135. PMID: 34075418 Free PMC article.		Declare and participate Interest is non-specific
Prof Andrew Owen (Member on therapeutic subpanel from March 2022)	Professor of Pharmacology, University of Liverpool	Non-Financial professional and personal	Quantitation of tizoxanide in multiple matrices to support cell culture, animal and human research. Neary M, Arshad U, Tatham L, Pertinez H, Box H, Rajoli RK, Valentijn A, Sharp J, Rannard SP, Biagini GA, Curley P, Owen A. bioRxiv. 2021 May 28:2021.05.27.445500. doi: 10.1101/2021.05.27.445500. Preprint. PMID: 34075381 Free PMC article.	May 2021	Declare and participate Interest will be kept under review depending on the matter under consideration. This specific intervention is not currently being considered as part of this guideline.
Prof Andrew Owen (Member on therapeutic subpanel from March 2022)	Professor of Pharmacology, University of Liverpool	Non-Financial professional and personal	Scalable nanoprecipitation of niclosamide and in vivo demonstration of long-acting delivery after intramuscular injection. Hobson JJ , Savage AC , Dwyer AB , Unsworth C , Massam J , Arshad U , Pertinez H , Box H , Tatham L , Rajoli RKR , Neary M , Sharp J , Valentijn A , David C , Curley P , Liptrott NJ , McDonald TO , Owen A , Rannard SP . Nanoscale. 2021 Apr 7;13(13):6410-6416. doi: 10.1039/d1nr00309g. Epub 2021 Mar 25. PMID: 33885522	April 2021	Declare and participate Interest will be kept under review depending on the matter under consideration. This specific intervention is not currently being considered as part of this guideline.

Name	Job title and organisation	Type of interest	Description of interest	Relevant dates	Comments
Prof Andrew Owen (Member on therapeutic subpanel from March 2022)	Professor of Pharmacology, University of Liverpool	Non-Financial professional and personal	<p>In vitro antiviral activity of the anti-HCV drugs daclatasvir and sofosbuvir against SARS-CoV-2, the aetiological agent of COVID-19.</p> <p>Sacramento CQ, Fintelman-Rodrigues N, Temerozo JR, Da Silva APD, Dias SDSG, da Silva CDS, Ferreira AC, Mattos M, Pão CRR, de Freitas CS, Soares VC, Hoelz LVB, Fernandes TVA, Branco FSC, Bastos MM, Boechat N, Saraiva FB, Ferreira MA, Jockusch S, Wang X, Tao C, Chien M, Xie W, Patel D, Garzia A, Tuschl T, Russo JJ, Rajoli RKR, Pedrosa CSG, Vitória G, Souza LRQ, Goto-Silva L, Guimarães MZ, Rehen SK, Owen A, Bozza FA, Bou-Habib DC, Ju J, Bozza PT, Souza TML. J Antimicrob Chemother. 2021 Jun 18;76(7):1874-1885. doi: 10.1093/jac/dkab072. PMID: 33880524 Free PMC article.</p>	June 2021	<p>Declare and participate</p> <p>Interest will be kept under review depending on the matter under consideration.</p> <p>This specific intervention is not currently being considered as part of this guideline.</p>
Prof Andrew Owen (Member on therapeutic subpanel from March 2022)	Professor of Pharmacology, University of Liverpool	Non-Financial professional and personal	<p>A living WHO guideline on drugs to prevent covid-19.</p> <p>Lamontagne F, Agoritsas T, Siemieniuk R, Rochweg B, Bartoszko J, Askie L, Macdonald H, Amin W, Bausch FJ, Burhan E, Cecconi M, Chanda D, Dat VQ, Du B, Geduld H, Gee P, Nerina H, Hashimi M, Hunt BJ, Kabra S, Kanda S, Kawano-Dourado L, Kim YJ, Kisson N, Kwizera A, Leo YS, Mahaka I, Manai H, Mino G, Nsutebu E, Pshenichnaya N, Qadir N, Ranganathan SS, Sabzwari S, Sarin R, Sharland M, Shen Y, Souza JP, Stegemann M, Ugarte S, Venkatapuram S, Vuyiseka D, Preller J, Brignardello-Petersen R, Kum E, Qasim A, Zeraatkar D, Owen A, Guyatt G, Lytvyn L, Diaz J, Vandvik PO, Jacobs M. BMJ. 2021 Mar 1;372:n526. doi: 10.1136/bmj.n526. PMID: 33649077</p>	March 2021	<p>Declare and participate</p> <p>Interest is non-specific</p>
Prof Andrew Owen (Member on therapeutic subpanel from March 2022)	Professor of Pharmacology, University of Liverpool	Non-Financial professional and personal	<p>Development of a highly sensitive bioanalytical assay for the quantification of favipiravir.</p> <p>Curley P, Neary M, Arshad U, Tatham L, Pertinez H, Box H, Rajoli RK, Valentijn A, Sharp J, Rannard SP, Owen A. bioRxiv. 2021 Feb 5:2021.02.03.429628. doi: 10.1101/2021.02.03.429628. Preprint. PMID: 33564761 Free PMC article.</p>	February 2021	<p>Declare and participate</p> <p>Interest is non-specific</p>
Prof Andrew Owen (Member on therapeutic subpanel from March 2022)	Professor of Pharmacology, University of Liverpool	Non-Financial professional and personal	<p>Optimisation and validation of a sensitive bioanalytical method for niclosamide.</p>	January 2021	<p>Declare and participate</p> <p>Interest will be kept under review depending</p>

Name	Job title and organisation	Type of interest	Description of interest	Relevant dates	Comments
subpanel from March 2022)			Arshad U, Pertinez H, Box H, Tatham L, Rajoli RK, Neary M, Sharp J, Valentijn A, Hobson J, Unsworth C, Dwyer A, Savage A, McDonald TO, Rannard SP, Curley P, Owen A. bioRxiv. 2021 Jan 15:2021.01.13.426426. doi: 10.1101/2021.01.13.426426. Preprint. PMID: 33469585 Free PMC article.		on the matter under consideration. This specific intervention is not currently being considered as part of this guideline.
Prof Andrew Owen (Member on therapeutic subpanel from March 2022)	Professor of Pharmacology, University of Liverpool	Non-Financial professional and personal	Efficacy and safety of nitazoxanide plus atazanavir/ritonavir for the treatment of moderate to severe COVID-19 (NACOVID): A structured summary of a study protocol for a randomised controlled trial. Olagunju A, Fowotade A, Olagunoye A, Ojo TO, Adefuye BO, Fagbamigbe AF, Adebisi AO, Olagunju OI, Ladipo OT, Akinloye A, Adeagbo BA, Onayade A, Bolaji OO, Happi C, Rannard S, Owen A. Trials. 2021 Jan 4;22(1):3. doi: 10.1186/s13063-020-04987-8. PMID: 33397457 Free PMC article.	January 2021	Declare and participate Interest will be kept under review depending on the matter under consideration. This specific intervention is not currently being considered as part of this guideline.
Prof Andrew Owen (Member on therapeutic subpanel from March 2022)	Professor of Pharmacology, University of Liverpool	Non-Financial professional and personal	Chasing COVID-19 chemotherapeutics without putting the cart before the horse. Rannard SP, McDonald TO, Owen A. Br J Clin Pharmacol. 2020 Nov 20;10.1111/bcp.14575. doi: 10.1111/bcp.14575. Online ahead of print. PMID: 33217038 Free PMC article. No abstract available.	November 2020	Declare and participate Interest is non-specific
Prof Andrew Owen (Member on therapeutic subpanel from March 2022)	Professor of Pharmacology, University of Liverpool	Non-Financial professional and personal	Dose prediction for repurposing nitazoxanide in SARS-CoV-2 treatment or chemoprophylaxis. Rajoli RKR, Pertinez H, Arshad U, Box H, Tatham L, Curley P, Neary M, Sharp J, Liptrott NJ, Valentijn A, David C, Rannard SP, Aljayyousi G, Pennington SH, Hill A, Boffito M, Ward SA, Khoo SH, Bray PG, O'Neill PM, Hong WD, Biagini GA, Owen A. Br J Clin Pharmacol. 2021 Apr;87(4):2078-2088. doi: 10.1111/bcp.14619. Epub 2020 Dec 1. PMID: 33085781 Free PMC article.	April 2021	Declare and participate Interest will be kept under review depending on the matter under consideration. This specific intervention is not currently being considered as part of this guideline.
Prof Andrew Owen (Member on therapeutic	Professor of Pharmacology,	Non-Financial professional and personal	A living WHO guideline on drugs for covid-19. Agarwal A, Rochweg B, Lamontagne F, Siemieniuk RA, Agoritsas T, Askie L, Lytvyn L, Leo YS, Macdonald H, Zeng L,	September 2020	Declare and participate

Name	Job title and organisation	Type of interest	Description of interest	Relevant dates	Comments
subpanel from March 2022)	University of Liverpool		Amin W, Barragan FAJ, Bausch FJ, Burhan E, Calfee CS, Cecconi M, Chanda D, Dat VQ, De Sutter A, Du B, Geduld H, Gee P, Gotte M, Harley N, Hashimi M, Hunt B, Jehan F, Kabra SK, Kanda S, Kim YJ, Kissoon N, Krishna S, Kuppalli K, Kwizera A, Lisboa T, Mahaka I, Manai H, Mino G, Nsutebu E, Preller J, Pshenichnaya N, Qadir N, Sabzwari S, Sarin R, Shankar-Hari M, Sharland M, Shen Y, Ranganathan SS, Souza JP, Stegemann M, Swanstrom R, Ugarte S, Venkatapuram S, Vuyiseka D, Wijewickrama A, Maguire B, Tran L, Zeraatkar D, Bartoszko JJ, Ge L, Brignardello-Petersen R, Owen A, Guyatt G, Diaz J, Kawano-Dourado L, Jacobs M, Vandvik PO. BMJ. 2020 Sep 4;370:m3379. doi: 10.1136/bmj.m3379. PMID: 32887691 Updated.		Interest is non-specific
Prof Andrew Owen (Member on therapeutic subpanel from March 2022)	Professor of Pharmacology, University of Liverpool	Non-Financial professional and personal	Review of safety and minimum pricing of nitazoxanide for potential treatment of COVID-19. Pepperrell T, Pilkington V, Owen A, Wang J, Hill AM. J Virus Erad. 2020 Apr 30;6(2):52-60. doi: 10.1016/S2055-6640(20)30017-0. PMID: 32405422 Free PMC article.	April 2020	Declare and participate Interest will be kept under review depending on the matter under consideration. This specific intervention is not currently being considered as part of this guideline.
Prof Andrew Owen (Member on therapeutic subpanel from March 2022)	Professor of Pharmacology, University of Liverpool	Non-Financial professional and personal	SARS-CoV-2 Omicron-B.1.1.529 Variant leads to less severe disease than Pango B and Delta variants strains in a mouse model of severe COVID-19 Eleanor G. Bentley, Adam Kirby, Parul Sharma, Anja Kipar, Daniele F. Mega, Chloe Bramwell, Rebekah Penrice-Randal, Tessa Prince, Jonathan C. Brown, Jie Zhou, Gavin R. Sreaton, Wendy S. Barclay, Andrew Owen, Julian A. Hiscox, James P. Stewart bioRxiv 2021.12.26.474085; doi: https://doi.org/10.1101/2021.12.26.474085	December 2021	Declare and participate Interest is non-specific

Name	Job title and organisation	Type of interest	Description of interest	Relevant dates	Comments
Prof Andrew Owen (Member on therapeutic subpanel from March 2022)	Professor of Pharmacology, University of Liverpool	Non-Financial professional and personal	Viral neuroinvasion and neurotropism without neuronal damage in the hACE2 mouse model of COVID-19 Frauke Seehusen, Jordan J. Clark, Parul Sharma, Krishanthi Subramaniam, Sabina Wunderlin Giuliani, Grant L. Hughes, Edward I. Patterson, Benedict D. Michael, Andrew Owen, Julian A. Hiscox, James P. Stewart, Anja Kipar bioRxiv 2021.04.16.440173; doi: https://doi.org/10.1101/2021.04.16.440173	April 2021	Declare and participate Interest is non-specific
Prof Andrew Owen (Member on therapeutic subpanel from March 2022)	Professor of Pharmacology, University of Liverpool	Non-Financial professional and personal	Lack of antiviral activity of probenecid in Vero E6 cells and Syrian golden hamsters: a need for better understanding of inter-lab differences in preclinical assays Helen Box, Shaun H Pennington, Edyta Kijak, Lee Tatham, Claire H Caygill, Rose C Lopeman, Laura N Jeffreys, Joanne Herriott, Joanne Sharp, Megan Neary, Anthony Valentijn, Henry Pertinez, Paul Curley, Usman Arshad, Rajith KR Rajoli, Steve Rannard, James P. Stewart, Giancarlo A Biagini, Andrew Owen bioRxiv 2022.03.03.482788; doi: https://doi.org/10.1101/2022.03.03.482788	March 2022	Declare and participate Interest is non-specific
Prof Andrew Owen (Member on therapeutic subpanel from March 2022)	Professor of Pharmacology, University of Liverpool	Non-Financial professional and personal	Sequential infection with influenza A virus followed by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) leads to more severe disease and encephalitis in a mouse model of COVID-19 Jordan J. Clark, Rebekah Penrice-Randal, Parul Sharma, Anja Kipar, Xiaofeng Dong, Shaun H. Pennington, Amy E. Marriott, Stefano Colombo, Andrew Davidson, Maia Kavanagh Williamson, David A. Matthews, Lance Turtle, Tessa Prince, Grant L. Hughes, Edward I. Patterson, Ghada Shawli, Krishanthi Subramaniam, Jo Sharp, Lynn McLaughlin, En-Min Zhou, Joseph D. Turner, Giancarlo Biagini, Andrew Owen, Julian A. Hiscox, James P. Stewart bioRxiv 2020.10.13.334532; doi: https://doi.org/10.1101/2020.10.13.334532	October 2020	Declare and participate Interest is non-specific

Name	Job title and organisation	Type of interest	Description of interest	Relevant dates	Comments
Prof Andrew Owen (Member on therapeutic subpanel from March 2022)	Professor of Pharmacology, University of Liverpool	Non-Financial professional and personal	Quantitation of tizoxanide in multiple matrices to support cell culture, animal and human research Megan Neary, Usman Arshad, Lee Tatham, Henry Pertinez, Helen Box, Rajith KR Rajoli, Anthony Valentijn, Joanne Sharp, Steve P Rannard, Giancarlo A Biagini, Paul Curley, Andrew Owen bioRxiv 2021.05.27.445500; doi: https://doi.org/10.1101/2021.05.27.445500	May 2021	Declare and participate Interest is non-specific
Prof Andrew Owen (Member on therapeutic subpanel from March 2022)	Professor of Pharmacology, University of Liverpool	Non-Financial professional and personal	Development of a highly sensitive bioanalytical assay for the quantification of favipiravir Paul Curley, Megan Neary, Usman Arshad, Lee Tatham, Henry Pertinez, Helen Box, Rajith KR Rajoli, Anthony Valentijn, Joanne Sharp, Steve P Rannard, Andrew Owen bioRxiv 2021.02.03.429628; doi: https://doi.org/10.1101/2021.02.03.429628	February 2021	Declare and participate Interest will be kept under review depending on the matter under consideration. This specific intervention is not currently being considered as part of this guideline.
Prof Andrew Owen (Member on therapeutic subpanel from March 2022)	Professor of Pharmacology, University of Liverpool	Non-Financial professional and personal	Optimisation and validation of a sensitive bioanalytical method for niclosamide Usman Arshad, Henry Pertinez, Helen Box, Lee Tatham, Rajith KR Rajoli, Megan Neary, Joanne Sharp, Anthony Valentijn, James Hobson, Catherine Unsworth, Andrew Dwyer, Alison Savage, Tom O Mcdonald, Steve P Rannard, Paul Curley, Andrew Owen bioRxiv 2021.01.13.426426; doi: https://doi.org/10.1101/2021.01.13.426426	January 2021	Declare and participate Interest will be kept under review depending on the matter under consideration. This specific intervention is not currently being considered as part of this guideline.
Prof Andrew Owen (Member on therapeutic subpanel from March 2022)	Professor of Pharmacology, University of Liverpool	Non-Financial professional and personal	Evaluation of intranasal nafamostat or camostat for SARS-CoV-2 chemoprophylaxis in Syrian golden hamsters M Neary, H Box, J Sharp, L Tatham, P Curley, J Herriott, E Kijak, U Arshad, JJ Hobson, RKR Rajoli, H Pertinez, A Valentijn, K Dhaliwal, F McCaughan, SP Rannard, A Kipar, JP Stewart, A Owen	July 2021	Declare and participate Interest will be kept under review depending on the matter under consideration.

Name	Job title and organisation	Type of interest	Description of interest	Relevant dates	Comments
			bioRxiv 2021.07.08.451654; doi: https://doi.org/10.1101/2021.07.08.451654		This specific intervention is not currently being considered as part of this guideline.
Prof Andrew Owen (Member on therapeutic subpanel from March 2022)	Professor of Pharmacology, University of Liverpool	Non-Financial professional and personal	Single-dose immunisation with a multimerised SARS-CoV-2 receptor binding domain (RBD) induces an enhanced and protective response in mice Ralf Salzer, Jordan J. Clark, Marina Vaysburd, Veronica T. Chang, Anna Albecka, Leo Kiss, Parul Sharma, Andres Gonzalez Llamazares, Anja Kipar, Julian A. Hiscox, Andrew Owen, A. Radu Aricescu, James P. Stewart, Leo C. James, Jan Löwe bioRxiv 2021.05.18.444622; doi: https://doi.org/10.1101/2021.05.18.444622	May 2021	Declare and participate Interest is non-specific
Prof Andrew Owen (Member on therapeutic subpanel from March 2022)	Professor of Pharmacology, University of Liverpool	Non-Financial professional and personal	Naturally-acquired immunity in Syrian Golden Hamsters provides protection from re-exposure to emerging heterosubtypic SARS-CoV-2 variants B.1.1.7 and B.1.351 Jordan J. Clark, Parul Sharma, Eleanor G. Bentley, Adam C. Harding, Anja Kipar, Megan Neary, Helen Box, Grant L. Hughes, Edward I. Patterson, Jo Sharp, Tulio de Oliveira, Alex Sigal, Julian A. Hiscox, William S. James, Miles W. Carroll, Andrew Owen, James P. Stewart bioRxiv 2021.03.10.434447; doi: https://doi.org/10.1101/2021.03.10.434447	March 2021	Declare and participate Interest is non-specific
Prof Andrew Owen (Member on therapeutic subpanel from March 2022)	Professor of Pharmacology, University of Liverpool	Non-Financial professional and personal	Unlike Chloroquine, mefloquine inhibits SARS-CoV-2 infection in physiologically relevant cells and does not induce viral variants Carolina Q. Sacramento, Natalia Fintelman-Rodrigues, Suelen S. G. Dias, Jairo R. Temerozo, Aline de Paula D. Da Silva, Carine S. da Silva, André C. Ferreira, Mayara Mattos, Vinicius C. Soares, Filipe Pereira-Dutra, Milene D. Miranda, Debora F. Barreto-Vieira, Marcos Alexandre N. da Silva, Suzana S. Santos, Mateo Torres, Rajith K R Rajoli, Alberto Paccanaro, Andrew Owen, Dumith Chequer Bou-Habib, Patrícia T. Bozza, Thiago Moreno L. Souza	July 2021	Declare and participate Interest will be kept under review depending on the matter under consideration. This specific intervention is not currently being

Name	Job title and organisation	Type of interest	Description of interest	Relevant dates	Comments
			bioRxiv 2021.07.21.451321; doi: https://doi.org/10.1101/2021.07.21.451321		considered as part of this guideline.
Prof Andrew Owen (Member on therapeutic subpanel from March 2022)	Professor of Pharmacology, University of Liverpool	Non-Financial professional and personal	The in vitro antiviral activity of the anti-hepatitis C virus (HCV) drugs daclatasvir and sofosbuvir against SARS-CoV-2 Carolina Q. Sacramento, Natalia Fintelman-Rodrigues, Jairo R. Temerozo, Aline de Paula Dias Da Silva, Suelen da Silva Gomes Dias, Carine dos Santos da Silva, André C. Ferreira, Mayara Mattos, Camila R. R. Pão, Caroline S. de Freitas, Vinicius Cardoso Soares, Lucas Villas Bôas Hoelz, Tácio Vinício Amorim Fernandes, Frederico Silva Castelo Branco, Mônica Macedo Bastos, Núbia Boechat, Felipe B. Saraiva, Marcelo Alves Ferreira, Rajith K. R. Rajoli, Carolina S. G. Pedrosa, Gabriela Vitória, Letícia R. Q. Souza, Livia Goto-Silva, Marília Zaluar Guimarães, Stevens K. Rehen, Andrew Owen, Fernando A. Bozza, Dumith Chequer Bou-Habib, Patrícia T. Bozza, Thiago Moreno L. Souza bioRxiv 2020.06.15.153411; doi: https://doi.org/10.1101/2020.06.15.153411	June 2020	Declare and participate Interest will be kept under review depending on the matter under consideration. This specific intervention is not currently being considered as part of this guideline.
Prof Andrew Owen (Member on therapeutic subpanel from March 2022)	Professor of Pharmacology, University of Liverpool	Non-Financial professional and personal	Efficacy and safety of nitazoxanide combined with ritonavir-boosted atazanavir for the treatment of mild to moderate COVID-19 Adeola Fowotade, Folasade Bamidele, Boluwatife Egbetola, Adeniyi Francis Fagbamigbe, Babatunde Ayodeji Adeagbo, Bolanle Olufunlola Adefuye, Ajibola Olagunoye, Temitope Olumuyiwa Ojo, Akindele Olupelumi Adebisi, Omobolanle Ibitayo Olagunju, Olabode Taiwo Ladipo, Abdulafeez Akinloye, Adedeji Onayade, Oluseye Oladotun Bolaji, Steve Rannard, Christian Happi, Andrew Owen, Adeniyi Olagunju medRxiv 2022.02.03.22270152; doi: https://doi.org/10.1101/2022.02.03.22270152	February 2022	Declare and participate Interest will be kept under review depending on the matter under consideration. This specific intervention is not currently being considered as part of this guideline.
Prof Andrew Owen (Member on therapeutic subpanel from March 2022)	Professor of Pharmacology, University of Liverpool	Non-Financial professional and personal	Randomised Controlled Trial of Intravenous Nafamostat Mesylate in COVID pneumonia: Phase 1b/2a Experimental Study to Investigate Safety, Pharmacokinetics and Pharmacodynamics	January 2021	Declare and participate Interest will be kept under review depending

Name	Job title and organisation	Type of interest	Description of interest	Relevant dates	Comments
			<p>Tom M. Quinn, Erin E. Gaughan, Annya Bruce, Jean Antonelli, Richard O'Connor, Feng Li, Sarah McNamara, Oliver Koch, Claire MacIntosh, David Dockrell I, Timothy Walsh, Kevin G. Blyth, Colin Church, Jürgen Schwarze, Cecilia Boz, Asta Valancute, Matthew Burgess, Philip Emanuel, Bethany Mills, Giulia Rinaldi, Gareth Hardisty, Ross Mills, Emily Findlay, Sunny Jabbal, Andrew Duncan, Sinéad Plant, Adam D. L. Marshall, Irene Young, Kay Russell, Emma Scholefield, Alastair F. Nimmo, Islom B. Nazarov, Grant C. Churchill, James S.O. McCullagh, Kourosh H. Ebrahimi, Colin Ferrett, Kate Templeton, Steve Rannard, Andrew Owen, Anne Moore, Keith Finlayson, Manu Shankar-Hari, John Norrie, Richard A. Parker, Ahsan R. Akram, Daniel C. Anthony, James W. Dear, Nik Hirani, Kevin Dhaliwal</p> <p>medRxiv 2021.10.06.21264648; doi: https://doi.org/10.1101/2021.10.06.21264648</p>		<p>on the matter under consideration.</p> <p>This specific intervention is not currently being considered as part of this guideline.</p>
<p>Prof Andrew Owen (Member on therapeutic subpanel from March 2022)</p>	<p>Professor of Pharmacology, University of Liverpool</p>	<p>Non-Financial professional and personal</p>	<p>Pharmacokinetic modelling to estimate intracellular favipiravir ribofuranosyl-5'-triphosphate exposure to support posology for SARS-CoV-2</p> <p>Henry Pertinez, Rajith KR Rajoli, Saye H Khoo, Andrew Owen</p> <p>medRxiv 2021.01.03.21249159; doi: https://doi.org/10.1101/2021.01.03.21249159</p>	<p>January 2021</p>	<p>Declare and participate</p> <p>Interest will be kept under review depending on the matter under consideration.</p> <p>This specific intervention is not currently being considered as part of this guideline.</p>
<p>Prof Andrew Owen (Member on therapeutic subpanel from March 2022)</p>	<p>Professor of Pharmacology, University of Liverpool</p>	<p>Non-Financial professional and personal</p>	<p>Modelling of Systemic versus Pulmonary Chloroquine Exposure in Man for COVID-19 Dose Selection</p> <p>Ghaith Aljayoussi, Rajith KR Rajoli, Henry Pertinez, Shaun H Pennington, W. David Hong, Paul M. O'Neill, Andrew Owen, Steve A Ward, Giancarlo A Biagini</p> <p>medRxiv 2020.04.24.20078741; doi: https://doi.org/10.1101/2020.04.24.20078741</p>	<p>April 2020</p>	<p>Declare and participate</p> <p>Interest will be kept under review depending on the matter under consideration.</p> <p>This specific intervention is not currently being</p>

Name	Job title and organisation	Type of interest	Description of interest	Relevant dates	Comments
					considered as part of this guideline.
Prof Andrew Owen (Member on therapeutic subpanel from March 2022)	Professor of Pharmacology, University of Liverpool	Non-Financial professional and personal	Dose prediction for repurposing nitazoxanide in SARS-CoV-2 treatment or chemoprophylaxis Rajith KR Rajoli, Henry Pertinez, Usman Arshad, Helen Box, Lee Tatham, Paul Curley, Megan Neary, Joanne Sharp, Neill J Liptrott, Anthony Valentijn, Christopher David, Steve P Rannard, Ghaith Aljayyousi, Shaun H Pennington, Andrew Hill, Marta Boffito, Stephen A Ward, Saye H Khoo, Patrick G Bray, Paul M. O'Neill, W. Dave Hong, Giancarlo Biagini, Andrew Owen medRxiv 2020.05.01.20087130; doi: https://doi.org/10.1101/2020.05.01.20087130	May 2021	Declare and participate Interest will be kept under review depending on the matter under consideration. This specific intervention is not currently being considered as part of this guideline.
Prof Andrew Owen (Member on therapeutic subpanel from March 2022)	Professor of Pharmacology, University of Liverpool	Non-Financial professional and personal	Prioritisation of potential anti-SARS-CoV-2 drug repurposing opportunities based on ability to achieve adequate plasma and target site concentrations derived from their established human pharmacokinetics Usman Arshad, Henry Pertinez, Helen Box, Lee Tatham, Rajith KR Rajoli, Paul Curley, Megan Neary, Joanne Sharp, Neill J Liptrott, Anthony Valentijn, Christopher David, Steve P Rannard, Paul O'Neill, Ghaith Aljayyousi, Shaun Pennington, Stephen A Ward, David J Back, Saye H Khoo, Patrick G Bray, Giancarlo Biagini, Andrew Owen medRxiv 2020.04.16.20068379; doi: https://doi.org/10.1101/2020.04.16.20068379	April 2020	Declare and participate Interest is non-specific
Prof Iain Squire (Vice-Chair and member on therapeutics subpanel)	Professor of Cardiovascular Medicine, University of Leicester	Direct, financial	Received honorarium for participation in educational events sponsored by Novartis – not related to COVID/management of COVID	December 2020	Declare and participate. Interest is non-specific
Prof Iain Squire (Vice-Chair and member on therapeutics subpanel)	Professor of Cardiovascular Medicine, University of Leicester	Direct, financial	Received honorarium for participation in educational events sponsored by Vifor - not related to COVID/management of COVID	January 2021	Declare and participate. Interest is non-specific

Name	Job title and organisation	Type of interest	Description of interest	Relevant dates	Comments
Prof Iain Squire (Vice-Chair and member on therapeutics subpanel)	Professor of Cardiovascular Medicine, University of Leicester	Direct, financial	I received payment for advice to AstraZeneca regarding the design of a clinical trial protocol, unrelated to COVID/management of COVID. All of these matters related to the management of chronic heart failure.	2020	Declare and participate. Interest is non-specific
Prof Iain Squire (Vice-Chair and member on therapeutics subpanel)	Professor of Cardiovascular Medicine, University of Leicester	Non-financial professional and personal	Involved in research which is supported by funding to my institution/department from (i) NIHR (ii) British Heart Foundation (iii) British Heart Foundation/British Society of Heart Failure (iv) Novartis (v) Boehringer Ingelheim. This funding is current and ongoing. The support from Novartis will cease during 2021 with the end of the relevant clinical trial. All of these relate to funding of research in heart failure / coronary disease and not in COVID	Ongoing	Declare and participate. Interest is non-specific
Prof Iain Squire (Vice-Chair and member on therapeutics subpanel)	Professor of Cardiovascular Medicine, University of Leicester	Indirect – financial	My institution (University of Leicester / University Hospitals of Leicester) is in receipt of funding for research in to COVID / management of COVID. I am not involved and am not aware of the details or the sources of these funds	Ongoing	Declare and participate. Funding direct to employer
Dr Ryan Zarychanski (Expert Witness)	Senior Investigator, REMAP-CAP, University of Manitoba	N/A	None	February 2021	Declare and participate The witness is providing expert advice to the committee and will not be contributing to recommendation drafting or decision making.
Shona Burman-Roy (Non-voting member on therapeutic subpanel)	NHS England Representative/Topic Adviser	Indirect interest	NHSE/I have published several policies relating to COVID -19 relating to service provision and therapeutic treatments – see https://www.england.nhs.uk/coronavirus/ for overarching recommendations and https://www.england.nhs.uk/coronavirus/clinical-policy/ for specific policies	March 2020 - ongoing	Declare and participate. Member is acting in an advisory capacity and is a non-voting member. Organisational interest declared on behalf of NHS England in the interests of transparency.
Miranda Matthews (Non-voting member on therapeutic)	NHS England Representative/Topic Adviser	Indirect, financial	Partner has 100 Pfizer shares from when he worked for the company.	02/08/1999- Ongoing	Declare and participate. Interest is indirect. Member is acting in an advisory capacity, is a

Name	Job title and organisation	Type of interest	Description of interest	Relevant dates	Comments
subpanel since January 2022)					non-voting member and does not determine wording of recommendations.
Miranda Matthews (Non-voting member on therapeutic subpanel since January 2022)	NHS England Representative/Topic Adviser	Non-financial professional and personal	NHSE/I have published several policies relating to COVID -19 relating to service provision and therapeutic treatments – see https://www.england.nhs.uk/coronavirus/ for overarching recommendations and https://www.england.nhs.uk/coronavirus/clinical-policy/ for specific policies	Start: January 2022 Ongoing	Declare and participate. Member is acting in an advisory capacity and is a non-voting member. Organisational interest declared on behalf of NHS England in the interests of transparency.
Malcolm Qualie (Non-voting member on therapeutic subpanel until January 2022)	NHS England Representative/Topic Adviser	Non-financial professional and personal	NHSE/I have published several policies relating to COVID -19 relating to service provision and therapeutic treatments – see https://www.england.nhs.uk/coronavirus/ for overarching recommendations and https://www.england.nhs.uk/coronavirus/clinical-policy/ for specific policies	March 2020-ongoing	Declare and participate. Member is acting in an advisory capacity and is a non-voting member. Organisational interest declared on behalf of NHS England in the interests of transparency.

Expert advisory co-opted members for specific topics

Name	Job title and organisation	Type of interest	Description of interest	Relevant dates	Comments
Darius Armstrong-James Johnson (co-opted for COVID-19 associated pulmonary aspergillosis)	Reader in Infectious Diseases and Medical Mycology, Imperial College London	Financial Interest	Share options in Pulmocide Ltd, investigational antifungal;	2017 - ongoing	Declare and partial exclusion. Rationale: excluded from drafting research recommendations in EAP 2 (16.11.21) on treatments.

Name	Job title and organisation	Type of interest	Description of interest	Relevant dates	Comments
					PC945 currently in phase II development as at 10.11.21
Dr Rónan Astin (co-opted for respiratory support and awake prone positioning)	Respiratory Consultant, University College London Hospitals NHS Foundation Trust	Direct Financial	I received an honorarium (£600) for a talk on High Flow Nasal Therapy (not relating to COVID) hosted by Breas	June 2021	Declare and participate Interest is non-specific for respiratory update
Prof Roopen Arya (Co-opted for heparins/VTE)	Professor of Thrombosis and Haemostasis, King's College Hospital	Direct, financial	Research support from Bayer for Investigator Sponsored Research – FIRST registry (long term VTE outcomes on rivaroxaban) (Bayer manufacture the anticoagulant rivaroxaban)	November 2015 – November 2020	Declare and participate Interest is non-specific for heparins/VTE
Prof Roopen Arya (Co-opted for heparins/VTE)	Professor of Thrombosis and Haemostasis, King's College Hospital	Direct, financial	Cardinal Health - speaker's fees for lectures on VTE (Cardinal Health manufacture mechanical devices for VTE prevention)	June 2020 – November 2020	Declare and participate Interest is non-specific for heparins/VTE
Prof Roopen Arya (Co-opted for heparins/VTE)	Professor of Thrombosis and Haemostasis, King's College Hospital	Direct, financial	Sanofi - speaker's fees for lectures/workshops on VTE (Sanofi manufacture the anticoagulant enoxaparin)	October 2019 – October 2020	Declare and participate Interest is non-specific for heparins/VTE
Dr Sabrina Bajwah (co-opted for respiratory support and awake prone positioning)	Clinical Senior Lecturer & Consultant Palliative Care, Kings College London & King's College NHS Trust	N/A	None	August 2021	Declare and participate
Reena Barai (co-opted for neutralising monoclonal	Community Pharmacist, S G Barai Pharmacy	Direct financial	I am a committee member of the PSNC, board member of the NPA. In these roles, I support the expansion of services available via Community Pharmacies.	April 2020 – ongoing	Declare and participate Interest is non-specific

Name	Job title and organisation	Type of interest	Description of interest	Relevant dates	Comments
antibodies in the community)					
Reena Barai (co-opted for neutralising monoclonal antibodies in the community)	Community Pharmacist, S G Barai Pharmacy	Direct financial	I have received honorariums for my expertise from Viatris (advisory board on what the current issues are in community pharmacy and how they can support this in general) and Novo Nordisk (advisory board for two conditions not related to COVID-19).	November 2019 & September 2021	Declare and participate Interest is non-specific
Reena Barai (co-opted for neutralising monoclonal antibodies in the community)	Community Pharmacist, S G Barai Pharmacy	Non-financial professional and personal	I registered to support the PRINCIPLE trial - but haven't recruited any patients to it	April 2020 – ongoing	Declare and participate Interest will be kept under review depending on matter under consideration
Reena Barai (co-opted for neutralising monoclonal antibodies in the community)	Community Pharmacist, S G Barai Pharmacy	Non-financial professional and personal	I am a trustee of Sutton Lodge, a charity for older people's welfare	2014-ongoing	Declare and participate Interest in non-specific
Dr Rupert Beale (co-opted for neutralising monoclonal antibodies in the community and anti-virals)	Consultant Nephrologist, Royal Free Hospital	Direct financial	Laboratory funding: Francis Crick Institute intramural funding	2019 - 2025	Declare and participate Interest in non-specific
Dr Rupert Beale (co-opted for neutralising monoclonal antibodies in the community and anti-virals)	Consultant Nephrologist, Royal Free Hospital	Direct financial	UKRI: SIREN, Co-I with Susan Hopkins at PHE/UKHSA, HICC/PITCH consortia,	2021 - 2023	Declare and participate This interest is non-specific to neutralising monoclonal antibodies or anti-virals under consideration
Dr Rupert Beale (co-opted for neutralising monoclonal antibodies in the community and anti-virals)	Consultant Nephrologist,	Direct financial	UKRI: Genotype to Phenotype UK "G2P-UK" National Virology Consortium. (Co-I with virologist colleagues from nine other UK institutions)	2021 - 2022	Declare and participate

Name	Job title and organisation	Type of interest	Description of interest	Relevant dates	Comments
antibodies in the community and anti-virals)	Royal Free Hospital				This interest is non-specific to neutralising monoclonal antibodies or anti-virals under consideration
Dr Rupert Beale (co-opted for neutralising monoclonal antibodies in the community and anti-virals)	Consultant Nephrologist, Royal Free Hospital	Direct financial	Kidney Research UK: "Immunogenicity of COVID-19 vaccination in patients with renal disease", (PI with E. Carr, S. McAdoo and M. Willicombe Co-Is)	2021 – 2022	Declare and participate This interest is non-specific to neutralising monoclonal antibodies or anti-virals under consideration
Dr Rupert Beale (op-opted for neutralising monoclonal antibodies in the community and anti-virals)	Consultant Nephrologist, Royal Free Hospital	Direct financial	MRC: Host factors for human polyomavirus replication & spread. Co-I with C. Crump	2019 - 2023	Declare and participate Interest is non-specific
Dr Rupert Beale (co-opted for neutralising monoclonal antibodies in the community and anti-virals)	Consultant Nephrologist, Royal Free Hospital	Non-financial professional and personal	Chair of Universities Testing Expert Panel Member of Advisory Group for Antibody Testing	TBC	Declare and participate Interest is non-specific
Dr Rupert Beale (co-opted for neutralising monoclonal antibodies in the community and anti-virals)	Consultant Nephrologist, Royal Free Hospital	Non-financial professional and personal	Member of COVID-19 nMABs Access and Policy National Expert Group Member of Higher Education Project Board for Mass Testing	TBC	Declare and participate Declaration is sufficient mitigation
Dr Rupert Beale (co-opted for neutralising monoclonal antibodies in the	Consultant Nephrologist, Royal Free Hospital	Non-financial professional and personal	Clinical lead for SARS-CoV-2 PCR Testing, Francis Crick Institute	TBC	Declare and participate Declaration is sufficient mitigation

Name	Job title and organisation	Type of interest	Description of interest	Relevant dates	Comments
community and anti-virals)					
Dr Rupert Beale (co-opted for neutralising monoclonal antibodies in the community and anti-virals)	Consultant Nephrologist, Royal Free Hospital	Non-financial professional and personal	Chair of Trial Steering Committee for PROphylaxis for paTiEnts at Risk of COVID-19 infecTion -V (PROTECT-V). https://clinicaltrials.gov/ct2/show/NCT04870333	ongoing	Declare and participate Interest is non-specific
Dr Rupert Beale (co-opted for neutralising monoclonal antibodies in the community and anti-virals)	Consultant Nephrologist, Royal Free Hospital	Non-financial professional and personal	PROTECT-V Fellow of the Royal College of Physicians	ongoing	Declare and participate Interest is non-specific
Dr Rupert Beale (co-opted for neutralising monoclonal antibodies in the community and anti-virals)	Consultant Nephrologist, Royal Free Hospital	Non-financial professional and personal	Member of the UK Kidney Association	ongoing	Declare and participate Interest is non-specific
Dr Rupert Beale (co-opted for neutralising monoclonal antibodies in the community and anti-virals)	Consultant Nephrologist, Royal Free Hospital	Non-financial professional and personal	Relevant recent academic publications: Carr EJ, Wu M, Harvey R, Wall EC, Kelly G, Hussain S, Howell M, Kassiotis G, Swanton C, Gandhi S, Bauer DL; Haemodialysis COVID-19 consortium; Crick COVID Immunity Pipeline, Billany RE, Graham-Brown MP, Beckett J, Bull K, Shankar S, Henderson S, Motallebzadeh R, Salama AD, Harper L, Mark PB, McAdoo S, Willicombe M, Beale R. Neutralising antibodies after COVID-19 vaccination in UK haemodialysis patients. Lancet. 2021 Sep 18;398(10305):1038-1041. Doi: 10.1016/S0140-6736(21)01854-7. Neutralising antibodies after C19 vaccination in UK haemodialysis patients	2018	Declare and participate Non-specific to neutralising monoclonal antibodies or the anti-virals under consideration
Dr Rupert Beale (co-opted for neutralising monoclonal antibodies in the	Consultant Nephrologist, Royal Free Hospital	Non-financial professional and personal	Publications on SARS-CoV-2, see Orcid 0000-0002-6705-8560 Non-specific to the topic under review		Declare and participate Publications reviewed and non-specific to

Name	Job title and organisation	Type of interest	Description of interest	Relevant dates	Comments
community and anti-virals)					neutralising monoclonal antibodies or the anti-virals under consideration
Dr Rupert Beale (co-opted for neutralising monoclonal antibodies in the community and anti-vitals)	Consultant Nephrologist, Royal Free Hospital	Direct, financial	Public opinion pieces: Multiple articles on Covid from March 2020 for London Review of Books, Spectator, Guardian.	2020	Declare and participate Opinions in publications reviewed and not deemed to present prejudicial view of evidence Non-specific to neutralising monoclonal antibodies or anti-virals
Dr Rupert Beale (co-opted for neutralising monoclonal antibodies in the community and anti-virals)	Consultant Nephrologist, Royal Free Hospital	Non-financial professional and personal	Podcasts with Robin Ince 'Cosmic Shambles', London Review of Books, Economist	20210	Declare and participate Interest is non-specific
Dr Rupert Beale (co-opted for neutralising monoclonal antibodies in the community and anti-virals)	Consultant Nephrologist, Royal Free Hospital	Indirect	I know Professor Herbert (Skip) Virgin of Vir Biotechnology through our shared academic interest in autophagy. We last met virtually on 1 July 2021 at an autophagy meeting I organised, the only time we have met during the pandemic. He is a professional scientific colleague, not a personal friend. We have never discussed any Covid therapeutics.	July 2021	Declare and participate Company manufacturer sotrovimab, this is an indirect interest with no direct financial gain Declaration is sufficient mitigation
Dr Rupert Beale (co-opted for neutralising monoclonal antibodies in the	Consultant Nephrologist, Royal Free Hospital	Non-financial professional and personal	Relevant recent academic publications: Wu, M., Wall, E. C., Carr, E. J., Harvey, R., Townsley, H., Mears, H. V., Aamds, L., Kjaer, S., Kelly, G., Warchael, S., Sawyer, C., Kavanagh, C., Queval, C. J., Ngai, Y., Hatipoglu, E., Ambrose, K., Hindmarsh, S., Beale, R., Gamblin, S., Howell, M., Kassiotis, G., Libri, V., Williams, B.,	January 2022	Declare and participate Paper not included in the review for neutralising monoclonal antibodies in the community. Interest

Name	Job title and organisation	Type of interest	Description of interest	Relevant dates	Comments
community and anti-virals)			Gandhi, S., Swanton, C., Bauer, D. L. V. 'Three-dose vaccination elicits neutralising antibodies against omicron' (2022) The Lancet. https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(22)00092-7/fulltext#%20		will be kept under review for future recommendations. Interest is non-specific to anti-virals under consideration.
Professor Stephen Brett (co-opted for respiratory support and awake prone positioning)	Consultant in Intensive Care Medicines, Imperial College Healthcare NHS Trust	Non-financial professional and personal	Local PI for NIHR funded trial – REMAP-CAP (Imperial led trial in the UK)	Ongoing	Declare and participate Interest is non-specific for respiratory update
Professor Stephen Brett (co-opted for respiratory support and awake prone positioning)	Consultant in Intensive Care Medicines, Imperial College Healthcare NHS Trust	Non-financial professional and personal	Local PI for GENOMIC- publicly funded trial of genetic susceptibility to COVID	Ongoing	Declare and participate Interest is non-specific for respiratory update
Professor Stephen Brett (co-opted for respiratory support and awake prone positioning)	Consultant in Intensive Care Medicines, Imperial College Healthcare NHS Trust	Non-financial professional and personal	Chief investigator for some locally funded qualitative studies in on recovery and long-term outcomes from COVID	Ongoing	Declare and participate Interest is non-specific for respiratory update
Professor Stephen Brett (co-opted for respiratory support and awake prone positioning)	Consultant in Intensive Care Medicines, Imperial College Healthcare NHS Trust	Non-financial professional and personal	Chief investigator for locally funded qualitative study of lived experience of hospital staff during COVID	Ongoing	Declare and participate Interest is non-specific for respiratory update
Professor Stephen Brett (co-opted for respiratory support and awake prone positioning)	Consultant in Intensive Care Medicines, Imperial College Healthcare NHS Trust	Direct-financial	Private practice in intensive care medicine at the Lister Hospital London and Hammersmith Hospital. Approximately <10% of my clinical work is private practice.	Declared 18/08/2021	Declare and participate Interest is non-specific to respiratory update and

Name	Job title and organisation	Type of interest	Description of interest	Relevant dates	Comments
					less than 10% of clinical work is private practice
Luigi Camporota (co-opted for Awake prone positioning and non-invasive respiratory support update)	Consultant Intensivist, Guy's and St Thomas' NHS Foundation Trust	Non-financial professional and personal	A number of publications in the field of prone position (both intubated and awake) and mechanical ventilation in COVID-19 – details of specific papers below.	February 2022	Declare and participate and keep under review pending further information. No publications authored by the member are currently included in the evidence base. Exclusion from future discussions as and when needed.
Luigi Camporota (co-opted for Awake prone positioning and non-invasive respiratory support update)	Consultant Intensivist, Guy's and St Thomas' NHS Foundation Trust	Non-financial professional and personal	Rossi S, Palumbo MM, Sverzellati N, Busana M, Malchiodi L, Bresciani P, Ceccarelli P, Sani E, Romitti F, Bonifazi M, Gattarello S, Steinberg I, Palermo P, Lazzari S, Collino F, Cressoni M, Herrmann P, Saager L, Meissner K, Quintel M, Camporota L, Marini JJ, Gattinoni L: Mechanisms of oxygenation responses to proning and recruitment in COVID-19 pneumonia. <i>Intensive Care Med</i> 2022, 48(1):56-66. https://www.ncbi.nlm.nih.gov/pubmed/34825929	February 2022	Declare and participate Interest is specific but not included in the evidence base for awake prone positioning. The content was not deemed to prejudice the panel member from approaching the evidence objectively.
Luigi Camporota (co-opted for Awake prone positioning and non-invasive respiratory support update)	Consultant Intensivist, Guy's and St Thomas' NHS Foundation Trust	Non-financial professional and personal	Camporota L, Sanderson B, Chiumello D, Terzi N, Argaud L, Rimmelé T, Metuor R, Verstraete A, Cour M, Bohe J, Piriou V, Beuret P, Guerin C: Prone Position in Coronavirus Disease 2019 and Noncoronavirus Disease 2019 Acute Respiratory Distress Syndrome: An International Multicenter Observational Comparative Study. <i>Crit Care Med</i> 2021. https://www.ncbi.nlm.nih.gov/pubmed/34582426	February 2022	Declare and participate Interest is specific but not included in the evidence base for awake prone positioning.
Luigi Camporota (co-opted for Awake prone positioning and non-invasive respiratory support update)	Consultant Intensivist, Guy's and St Thomas' NHS Foundation Trust	Non-financial professional and personal	Gattinoni L, Chiumello D, Caironi P, Busana M, Romitti F, Brazzi L, Camporota L: COVID-19 pneumonia: different respiratory treatments for different phenotypes? <i>Intensive Care Med</i> 2020, 46(6):1099-1102. https://www.ncbi.nlm.nih.gov/pubmed/32291463	February 2022	Declare and participate Interest is specific but not included in the evidence base for the non-invasive

Name	Job title and organisation	Type of interest	Description of interest	Relevant dates	Comments
					respiratory support update. The content was not deemed to prejudice the panel member from approaching the evidence objectively.
Luigi Camporota (co-opted for Awake prone positioning and non-invasive respiratory support update)	Consultant Intensivist, Guy's and St Thomas' NHS Foundation Trust	Non-financial professional and personal	Formenti F, Camporota L: Prone to de-stress the vulnerable lung. <i>Exp Physiol</i> 2020. https://www.ncbi.nlm.nih.gov/pubmed/33369796	February 2022	Declare and participate Interest is non-specific
Luigi Camporota (co-opted for Awake prone positioning and non-invasive respiratory support update)	Consultant Intensivist, Guy's and St Thomas' NHS Foundation Trust	Non-financial professional and personal	Stripoli T, Spadaro S, Di Mussi R, Volta CA, Trerotoli P, De Carlo F, Iannuzziello R, Sechi F, Pierucci P, Staffieri F, Bruno F, Camporota L, Grasso S: High-flow oxygen therapy in tracheostomized patients at high risk of weaning failure. <i>Ann Intensive Care</i> 2019, 9(1):4. https://www.ncbi.nlm.nih.gov/pubmed/30617626	February 2022	Declare and participate Interest is non-specific
Deborah Dykes (co-opted for respiratory support and awake prone positioning)	Clinical Specialist Respiratory Physiotherapist, University Hospitals Sussex NHS Foundation Trust, St Richard's Hospital	Non-financial professional and personal	I work within a Quality Improvement Role of KSS Critical Care ODN and have been doing staff experience surveys related to CPAP / HFNO as part of a service evaluation. The aim of this work is to share learning and not to assess or recommend a particular intervention.	Declared 19/08/2021	Declare and participate This is part of member's salaried position and does not consider clinical effectiveness.
Hiten Dodhia (co-opted for vitamin D)	Consultant in Public Health, London Borough of Lambeth	Non-financial professional and personal	Comparison of presentations to the emergency department during the COVID-19 pandemic (COPED-C) March 2021 Journal of Public Health 43(11) DOI: 10.1093/pubmed/fdab059 A Kociejowski C Hobart J Raeesa Show et al	Declared 15/06/2022	Declare and participate Interest is non-specific to the review on vitamin D

Name	Job title and organisation	Type of interest	Description of interest	Relevant dates	Comments
Hiten Dodhia (co-opted for vitamin D)	Consultant in Public Health, London Borough of Lambeth	Non-financial professional and personal	Racism as a social determinant: Covid-19 and its impacts on racial/ethnic minorities Article December 2020 Karim Mitha Kaveri Qureshi Shelina Adatia Hiten Dodhia (https://archive.discoverysociety.org/2020/12/22/racism-as-a-social-determinant-covid-19-and-its-impacts-on-racial-ethnic-minorities/)	Declared 15/06/2022	Declare and participate Interest is non-specific to the review on vitamin D
Hiten Dodhia (co-opted for vitamin D)	Consultant in Public Health, London Borough of Lambeth	Non-financial professional and personal	A case-control and cohort study to determine the relationship between ethnic background and severe COVID-19 EClinicalMedicine (2020), https://doi.org/10.1016/j.eclinm.2020.100574 EClinicalMedicine 000 (2020) 100574 https://www.journals.elsevier.com/eclinicalmedicine	Declared 15/06/2022	Declare and participate Interest is non-specific to the review on vitamin D
Nandan Gautam (co-opted for respiratory support and awake prone positioning)	Consultant in General Medicine and Intensive Care, Queen Elizabeth Hospital, Birmingham	N/A	None	August 2021	Declare and participate
Dr Anna Goodman (co-opted for ivermectin and neutralising monoclonal antibodies in the community)	Consultant in Infectious Diseases, Guys & St Thomas NHS Trust.	Direct, financial	I am named as an inventor on a patent covering use of a particular promoter construct that is often used in ChAdOx1-vectored vaccines and is incorporated in the ChAdOx1 nCoV-19 vaccine. I may benefit from royalty income paid to the University of Oxford from sales of this vaccine by AstraZeneca and its sublicensees under the University's revenue sharing policy	2010 – ongoing	Declare and participate Declaration is sufficient mitigation; vaccines are not within scope
Dr Anna Goodman (co-opted for ivermectin and neutralising monoclonal antibodies in the community)	Consultant in Infectious Diseases, Guys & St Thomas NHS Trust.	Non-financial professional and personal	Guidelines' secretary British Infection Association	2016 – ongoing	Declare and participate Interest is non-specific
Dr Anna Goodman (co-opted for ivermectin and neutralising monoclonal antibodies in the community)	Consultant in Infectious Diseases, Guys & St Thomas NHS Trust.	Non-financial professional and personal	Associate Professor at MRC CTU at UCL developing projects on COVID-19 and the treatment (ACTT, TICO trials- named author on papers on this topic)	2020 - ongoing	Declare and participate Interest is out of scope for ivermectin

Name	Job title and organisation	Type of interest	Description of interest	Relevant dates	Comments
antibodies in community)					
Dr Anna Goodman (co-opted for ivermectin and neutralising monoclonal antibodies in the community)	Consultant in Infectious Diseases, Guys & St Thomas NHS Trust.	Non-financial professional and personal	I am a co-author on the international writing group for the TICO trial and national medical officer in the UK. Within this platform trial a range of monoclonal antibodies against SARS-Co-V2 have been tested.	March 2020 – ongoing	Declare and participate Interest is non-specific to this review as limited to hospitalised patients
Dr Anna Goodman (co-opted for ivermectin and neutralising monoclonal antibodies in the community)	Consultant in Infectious Diseases, Guys & St Thomas NHS Trust.	Non-financial professional and personal	I am an infectious diseases physician and clinical academic with a wide range of interests in COVID-19. I am principal investigator at my hospital site for a range of COVID-19 vaccine trials and the TICO trial which includes monoclonal antibodies in the platform.	2011 – ongoing	Declare and participate Interest is non-specific to the review on neutralising monoclonal antibodies for people not in hospital as it is limited to hospitalised
Dr Anna Goodman (co-opted for ivermectin and neutralising monoclonal antibodies in the community)	Consultant in Infectious Diseases, Guys & St Thomas NHS Trust.	Indirect	I give talks on vaccines- once I received an Honorarium which I donated directly to Refugees at Home but usually I avoid receipt of Honorariums	2020 – ongoing	Declare and participate Interest is non-specific
Dr Anna Goodman (co-opted for ivermectin and neutralising monoclonal antibodies in the community)	Consultant in Infectious Diseases, Guys & St Thomas NHS Trust.	Non-financial professional and personal	Clinical lead of CMDU at St Thomas. and is local trial PI for PANORAMIC trial	November 2021 – ongoing	Declare and participate Interest is non-specific to ivermectin and neutralising monoclonal antibodies in the community.
Dr Anna Goodman (co-opted for ivermectin and neutralising monoclonal antibodies in the community)	Consultant in Infectious Diseases, Guys & St Thomas NHS Trust.	Direct, financial	Novavax grant to my institution (via NIHR - non-commercial) to support clinical trials of COVID vaccines	October 2020 – ongoing	Declare and participate Funding direct to employer

Name	Job title and organisation	Type of interest	Description of interest	Relevant dates	Comments
Jillian Hartin (co-opted for respiratory support and awake prone positioning)	Lead Nurse, Patient Emergency Response and Resuscitation Team , UCLH NHS Foundation Trust	N/A	None	August 2021	Declare and participate
Professor Elizabeth M. Johnson (co-opted for COVID-19 associated pulmonary aspergillosis)	Head of the UK HSA Mycology Reference Laboratory, UK Health Security Agency (UK HSA previously Public Health England)	Indirect financial	I run the UK National Mycology Reference Laboratory which is one of several Mycology laboratories in the UK that undertakes biomarker testing which is a charged-for service. This is therefore one of the income streams of the laboratory which is used to cover laboratory costs and overheads. Our workload has already increased markedly due to publications about the utility of biomarker testing in CAPA but NICE guidelines may lead to even greater awareness. However, laboratories can if they wish would introduce this testing themselves and do have a choice of where to send samples so we do not have a monopoly.	2000 - ongoing	Declare and partial exclusion Participate in discussion of evidence, exclusion from drafting of recommendations on diagnostics at EAP 2 (16.11.21)
Professor Elizabeth M. Johnson (co-opted for COVID-19 associated pulmonary aspergillosis)	Head of the UK HSA Mycology Reference Laboratory, UK Health Security Agency (UK HSA previously Public Health England)	Direct non-financial	Employed by UK Health Security Agency (previously Public Health England) which is an executive agency sponsored by the Department of Health and Social Care (DHSC).	2000 - ongoing	Declare and participate Interest is non-specific
Dr Leticia Kawano Dourado (co-opted for ivermectin – advisory capacity only)	Medical Researcher, HCOR Research Institute, Hospital do Coracao, Sao Paulo, Brazil	Direct, financial	Research funding from PROADI-SUS program conduct the RENOVATE trial NCT03643939, a trial in acute resp failure, testing HFNC vs NIPPV (Brazilian Ministry of Health) from 2018 - actual	2018 – ongoing	Declare and participate Interest is non-specific
Dr Leticia Kawano Dourado (co-opted for ivermectin – advisory capacity only)	Medical Researcher, HCOR Research Institute, Hospital do Coracao, Sao Paulo, Brazil	Direct, financial	European Respiratory Society from September 2020- September 2021 (ceased) - awarded the ERS long term scholarship to conduct research here in France on telomere-related genetics in pulmonary fibrosis	Sept 2020 – Sept 2021	Declare and participate Interest is non-specific
Dr Leticia Kawano Dourado (co-opted	Medical Researcher,	Direct, financial	Funding for EVITA prospective cohort NCT04961944 on hypersensitivity pneumonitis - from Boehringer Ingelheim from 2021	2021 – ongoing	Declare and participate

Name	Job title and organisation	Type of interest	Description of interest	Relevant dates	Comments
for ivermectin – advisory capacity only)	HCOR Research Institute, Hospital do Coracao, Sao Paulo, Brazil				Interest is non-specific
Dr Leticia Kawano Dourado (co-opted for ivermectin – advisory capacity only)	Medical Researcher, HCOR Research Institute, Hospital do Coracao, Sao Paulo, Brazil	Direct, financial	Funding for BERTHA prospective cohort NCT04136223 on rheumatoid arthritis associated interstitial pneumonitis from Bristol-Myers Squibb from 2019	2019 - ongoing	Declare and participate Interest is non-specific
Dr Leticia Kawano Dourado (co-opted for ivermectin – advisory capacity only)	Medical Researcher, HCOR Research Institute, Hospital do Coracao, Sao Paulo, Brazil	Direct, financial	<p>Speaker fees and/or advisory board participation from Boehringer Ingelheim, Roche, Bristol-Myers Squibb, Lilly, Alnylam, Gilead. Presentations were either on Rheumatoid-arthritis associated interstitial lung disease, pulmonary fibrosis or COVID-19. None related to ivermectin.</p> <p>For advisory board participations, the subject was the same as stated above, none related to ivermectin. More specifically for COVID-19 lectures, content was the pulmonary involvement in covid, risk of pulmonary fibrosis associated with COVID-19.</p> <p>For Gilead (remdesivir's company) treatment options were mentioned, but nothing related to ivermectin.</p> <p>I do not have any financial relationship with pharmas producing ivermectin nor I have been involved in activities specifically discussing ivermectin for covid</p>	Ongoing	Declare and participate Interest is non-specific and declaration is sufficient mitigation
Dr Leticia Kawano Dourado (co-opted for ivermectin – advisory capacity only)	Medical Researcher, HCOR Research Institute, Hospital do Coracao, Sao Paulo, Brazil	Non-financial professional and personal	Non-financial research support from Fisher & Paykel from 2018 – actual. F&P donated the high flow nasal catheters for the RENOVATE trial (described above).	2018 – ongoing	Declare and participate Interest is non-specific
Dr Matthew Knight (co-opted for anti-virals)	Consultant Respiratory Physician, West Hertfordshire Hospitals NHS Trust	Non-financial professional and personal	We have also participated in research and published on the remote management of pneumothorax (pre Covid) as well as a series of short publications on the use of PCR in routine viral screening (2016-19) - all done via WHHT NHS Trust - this being pre-Covid work - published via European Respiratory Society.	Start: March 2020 Ongoing	Declare and participate Interest is non-specific

Name	Job title and organisation	Type of interest	Description of interest	Relevant dates	Comments
Dr Matthew Knight (co-opted for anti-virals)	Consultant Respiratory Physician, West Hertfordshire Hospitals NHS Trust	Non-financial professional and personal	I have given a number of webinars on behalf of Huma, Medopad and NHSX on remote and virtual management of Covid 19. These were always done as a representative of my NHS Trust. Neither my trust nor I have received any payment and as the webinars were all remote there were no expenses or any hospitality to declare.	Start: March 2020 Ongoing	Declare and participate Interest is non-specific
Dr Matthew Knight (co-opted for anti-virals)	Consultant Respiratory Physician, West Hertfordshire Hospitals NHS Trust	Non-financial professional and personal	My NHS trust launched a virtual hospital for managing patients with C19 (now also COPD and heart failure).	Start: March 2020 Ongoing	Declare and participate Interest is non-specific
Dr Matthew Knight (co-opted for anti-virals)	Consultant Respiratory Physician, West Hertfordshire Hospitals NHS Trust	Direct, financial	Private work at Clementine Churchill hospital – usual amount of 3 hours per week of patient care (+ administration and travel time) – however on sabbatical until after Easter 2022. I do not do any acute care in the private setting, although it is plausible that post return to private practice later this year I will see patients with Long Covid/ prolonged post covid 19 syndrome.	Start: March 2020 Ongoing	Declare and participate Interest is non-specific. Private practice is limited and not specific to condition under consideration.
Dr Matthew Knight (co-opted for anti-virals)	Consultant Respiratory Physician, West Hertfordshire Hospitals NHS Trust	Indirect financial	Outside of my NHS trust I sit on the board of a virtual healthcare provider (medefer) as a medical director (part time) - Medefer does not manage any patients with acute disease, and at the current time does not provide any covid care (unless patients are referred with post covid syndrome). Medefer only provides services to the NHS.	Start: March 2020 Ongoing	Declare and participate Interest is non-specific to anti virals under consideration.
Dr Matthew Knight (co-opted for anti-virals)	Consultant Respiratory Physician, West Hertfordshire Hospitals NHS Trust	Indirect financial	I sit on the board of Penrose Care, a provider of domiciliary care in NW London - this does not provide any medical services. During the pandemic I did provide advice to the company on protecting staff and clients from Covid (masks, ventilation) however neither the company nor I made any profit from masks or ventilation equipment.	Start: March 2020 Ongoing	Declare and participate Interest is non-specific
Dr Matthew Knight (co-opted for anti-virals)	Consultant Respiratory Physician, West Hertfordshire Hospitals NHS Trust	Indirect financial	I have provided clinical advisory services to a mental health company (SupportRoom) that runs online CBT support service- they do not (and to the best of my knowledge have no plans) provide any services in anyway related to C-19.	Start: March 2020 Ongoing	Declare and participate Interest is non-specific

Name	Job title and organisation	Type of interest	Description of interest	Relevant dates	Comments
Dr Matthew Knight (co-opted for anti-virals)	Consultant Respiratory Physician, West Hertfordshire Hospitals NHS Trust	Non-financial professional and personal	Relevant academic publication: Steven P Walker, Emma Keenan, Oliver Bintcliffe, Andrew E Stanton, Mark Roberts, Justin Pepperell, Ian Fairbairn, Edward McKeown, James Goldring, Nadeem Maddekar, James Walters, Alex West, Amrithraj Bhatta, Matthew Knight, Rachel Mercer, Rob Hallifax, Paul White, Robert F Miller, Najib M Rahman, Nick A Maskell (2021) 'Ambulatory management of secondary spontaneous pneumothorax: a randomised controlled trial'. European Respiratory Journal, 57, 6.	2021	Declare and participate Interest is non-specific to anti-virals under consideration
Dr Matthew Knight (co-opted for anti-virals)	Consultant Respiratory Physician, West Hertfordshire Hospitals NHS Trust	Non-financial professional and personal	Relevant academic publication: Chua, F; Draper, A; Knight, M; Mogal, R; Singh, J; Spencer, LG; Thwaite, E; Vaghela, T; Mitchell, H; Calmonson, S (2021) 'P256 Prognostication in COVID-19: a prospectively derived and externally validated risk prediction score for in-hospital death' Thorax, BMJ Publishing Group Ltd	2021	Declare and participate Interest is non-specific to anti-virals under consideration
Dr Matthew Knight (co-opted for anti-virals)	Consultant Respiratory Physician, West Hertfordshire Hospitals NHS Trust	Non-financial professional and personal	Relevant academic publication: Kalin, Asli; Javid, Babak; Knight, Matthew; Inada-Kim, Matt; Greenhalgh, Trisha (2021) 'Direct and indirect evidence of efficacy and safety of rapid exercise tests for exertional desaturation in Covid-19: a rapid systematic review' Systematic Reviews, 10, 1	2021	Declare and participate Interest is non-specific to anti-virals under consideration
Dr Matthew Knight (co-opted for anti-virals)	Consultant Respiratory Physician, West Hertfordshire Hospitals NHS Trust	Non-financial professional and personal	Relevant academic publication: Chua, Felix; Vancheeswaran, Rama; Draper, Adrian; Vaghela, Tejal; Knight, Matthew; Mogal, Rahul; Singh, Jaswinder; Spencer, Lisa G; Thwaite, Erica; Mitchell, Harry (2021) 'Early prognostication of COVID-19 to guide hospitalisation versus outpatient monitoring using a point-of-test risk prediction score' Thorax, 76, 7: 696-703	2021	Declare and participate Interest is non-specific to anti-virals under consideration
Dr Matthew Knight (co-opted for anti-virals)	Consultant Respiratory Physician, West Hertfordshire Hospitals NHS Trust	Non-financial professional and personal	Relevant academic publication: Shah, Sachin Shailendra; Gvozdanovic, Andrew; Knight, Matthew; Gagnon, Julien. (2021) 'Mobile App-Based Remote Patient Monitoring in Acute Medical Conditions: Prospective Feasibility Study Exploring Digital Health Solutions on Clinical Workload During the COVID Crisis' JMIR formative research, 5, 1: e23190	2021	Declare and participate Interest is non-specific to anti-virals under consideration
Dr Matthew Knight (co-opted for anti-virals)	Consultant Respiratory Physician, West Hertfordshire Hospitals NHS Trust	Non-financial professional and personal	Relevant academic publication: Greenhalgh, Trisha; Knight, Matthew; Inada-Kim, Matt; Fulop, Naomi J; Leach, Jonathan; Vindrola-Padros, Cecilia (2021) 'Remote management of covid-19 using home pulse oximetry and virtual ward support' BMJ Publishing Group, 372	2021	Declare and participate. Interest is non-specific to anti-virals under consideration

Name	Job title and organisation	Type of interest	Description of interest	Relevant dates	Comments
Dr Matthew Knight (co-opted for anti-virals)	Consultant Respiratory Physician, West Hertfordshire Hospitals NHS Trust	Non-financial professional and personal	Relevant academic publication: Francis, Nick A; Stuart, Beth; Knight, Matthew; Vancheeswaran, Rama; Oliver, Charles; Willcox, Merlin; Barlow, Andrew; Moore, Michael. (2021) 'Predictors of clinical deterioration in patients with suspected COVID-19 managed in a 'virtual hospital' setting: a cohort study' BMJ Open, 11, 3: e045356	2021	Declare and participate Interest is non-specific to anti-virals under consideration
Dr Matthew Knight (co-opted for anti-virals)	Consultant Respiratory Physician, West Hertfordshire Hospitals NHS Trust	Non-financial professional and personal	Relevant academic publication: Knight, Matthew; Greenhalgh, Trisha; Fulop, Naomi J; Inada-Kim, Matt. (2021) 'Authors' reply to Moyle and Ashworth' BMJ Publishing Group, 373	2021	Declare and participate. Interest is non-specific to anti-virals under consideration
Dr Matthew Knight (co-opted for anti-virals)	Consultant Respiratory Physician, West Hertfordshire Hospitals NHS Trust	Non-financial professional and personal	Relevant academic publication: Knight, MJ; Subbe, CP; Inada-Kim, M (2021) 'Racial discrepancies in oximetry: where do we stand?' Anaesthesia	2021	Declare and participate. Interest is non-specific to anti-virals under consideration
Dr Matthew Knight (co-opted for anti-virals)	Consultant Respiratory Physician, West Hertfordshire Hospitals NHS Trust Non-financial professional and personal Trust	Non-financial professional and personal	Relevant academic publication: Knight, Matthew; Vancheeswaran, Rama. (2021) 'Post-acute covid-19 in primary care' BMJ Publishing Group, 375	2021	Declare and participate. Interest is non-specific to anti-virals under consideration
Dr Matthew Knight (co-opted for anti-virals)	Consultant Respiratory Physician, West Hertfordshire Hospitals NHS Trust	Non-financial professional and personal	Relevant academic publication: Rob J Hallifax, Edward McKeown, Parthipan Sivakumar, Ian Fairbairn, Christy Peter, Andrew Leitch, Matthew Knight, Andrew Stanton, Asim Ijaz, Stefan Marciniak, James Cameron, Amrithraj Bhatta, Kevin G Blyth, Raja Reddy, Marie-Clare Harris, Nadeem Maddekar, Steven Walker, Alex West, Magda Laskawiec-Szkonter, John P Corcoran, Stephen Gerry, Corran Roberts, John E Harvey, Nick Maskell, Robert F Miller, Najib M Rahman. (2020) 'Ambulatory management of primary spontaneous pneumothorax: an open-label, randomised controlled trial' The Lancet, 396: 10243: pp 39-49	2020	Declare and participate. Interest is non-specific to anti-virals under consideration
Dr Matthew Knight (co-opted for anti-virals)	Consultant Respiratory Physician, West Hertfordshire	Non-financial professional and personal	Relevant academic publication: Greenhalgh, Trisha; Javid, Babak; Knight, Matthew; Inada-Kim, Matt (2020) 'What is the efficacy and safety of rapid exercise tests for exertional desaturation in covid-19'	2020	Declare and participate.

Name	Job title and organisation	Type of interest	Description of interest	Relevant dates	Comments
	Hospitals NHS Trust		Centre for Evidence-Based Medicine, Nuffield Department of Primary Care Health Sciences, University of Oxford		Interest is non-specific to anti-virals under consideration
Dr Matthew Knight (co-opted for anti-virals)	Consultant Respiratory Physician, West Hertfordshire Hospitals NHS Trust	Non-financial professional and personal	Relevant academic publication: Matthew Knight, David Evans, Rama Vancheeswaran, Michael Van der Watt, Alex Newland Smith, Charlie Oliver, Philip Kelso, Chantoy Spencer, Andrew Barlow (2020) 'A virtual hospital model can help tackle the covid-19 pandemic' HSJ: https://www.hsj.co.uk/technology-and-innovation/a-virtual-hospital-model-can-help-tackle-the-covid-19-pandemic/7027340.article	2020	Declare and participate. Interest is non-specific to anti-virals under consideration
Dr Matthew Knight (co-opted for anti-virals)	Consultant Respiratory Physician, West Hertfordshire Hospitals NHS Trust	Non-financial professional and personal	Relevant academic publication: Matthew Knight, Rama Vancheeswaran, Steven Joseph, M O'Neill. David Evans, Chantoy Spencer, Fran Vertler and Andy Barlow. (2020) 'Proof that virtual clinics can reduce waiting lists' HSJ: https://www.hsj.co.uk/technology-and-innovation/proof-that-virtual-clinics-can-reduce-waiting-lists/7028012.article	2020	Declare and participate. Interest is non-specific to anti-virals under consideration.
Dr Matthew Knight (co-opted for anti-virals)	Consultant Respiratory Physician, West Hertfordshire Hospitals NHS Trust	Non-financial professional and personal	Relevant academic publication: Hallifax, R; McKeown, E; Sivakumar, P; Fairbairn, I; Peter, C; Leitch, A; Knight, MJ; Stanton, AE; Ijaz, A; Marciniak, SJ (2020) 'Randomised Trial for Ambulatory Management of Primary Spontaneous Pneumothorax' Epidemiology, Diagnosis, And Treatment In Pleural Disease And IP: A1124	2020	Declare and participate. Interest is non-specific to anti-virals under consideration.
Dr Matthew Knight (co-opted for anti-virals)	Consultant Respiratory Physician, West Hertfordshire Hospitals NHS Trust	Non-financial professional and personal	Relevant academic publication: Greenhalgh, Trisha; Knight, Matthew; Buxton, Maria; Husain, Laiba (2020) 'Management of post-acute covid-19 in primary care' BMJ Publishing Group, 370	2020	Declare and participate. Interest is non-specific to anti-virals under consideration
Dr Matthew Knight (co-opted for anti-virals)	Consultant Respiratory Physician, West Hertfordshire Hospitals NHS Trust	Non-financial professional and personal	Relevant academic publication: Hallifax, Rob; Mckeown, Edward; Sivakumar, Parthipan; Fairburn, Ian; Peter, Christy; Leitch, Andrew; Knight, Matthew; Stanton, Andrew; Ijaz, Azim; Marciniak, Stefan (2020) 'Late Breaking Abstract-Randomised trial of ambulatory management of primary spontaneous pneumothorax' European Respiratory Society	2020	Declare and participate. Interest is non-specific to anti-virals under consideration
Dr Matthew Knight (co-opted for anti-virals)	Consultant Respiratory Physician, West Hertfordshire Hospitals NHS Trust	Non-financial professional and personal	Relevant academic publication: Francis, Nick A; Stuart, Beth; Knight, Matthew; Vancheeswaran, Rama; Oliver, Charles; Willcox, Merlin; Barlow, Andrew; Moore, Michael (2020) 'Predictors of adverse outcome in patients with suspected COVID-19 managed in a virtual hospital setting: a cohort study' Cold Spring Harbor Laboratory Press	2020	Declare and participate. Interest is non-specific to anti-virals under consideration

Name	Job title and organisation	Type of interest	Description of interest	Relevant dates	Comments
Dr Matthew Knight (co-opted for anti-virals)	Consultant Respiratory Physician, West Hertfordshire Hospitals NHS Trust	Non-financial professional and personal	Relevant academic publication: Greenhalgh, Trish; Javid, Babak; Knight, Matthew; Inada-Kim, Matthew (2020) 'What is the efficacy and safety of rapid exercise tests for exertional desaturation in Covid-19: a rapid review protocol' Cold Spring Harbor Laboratory Press	2020	Declare and participate. Interest is non-specific to anti-virals under consideration
Dr Matthew Knight (co-opted for anti-virals)	Consultant Respiratory Physician, West Hertfordshire Hospitals NHS Trust	Non-financial professional and personal	Relevant academic publication: Vancheeswaran, Rama; Willcox, Merlin L; Stuart, Beth; Knight, Matthew; Kandil, Hala; Barlow, Andrew; Patel, Mayon Hareh; Stockham, Jade; O'Neill, Aisling; Clark, Tristan Luke (2020) 'Accuracy of Rapid Point-of-Care Antibody Test in patients with suspected or confirmed COVID-19' Cold Spring Harbor Laboratory Press	2020	Declare and participate. Interest is non-specific to anti-virals under consideration
Dr Matthew Knight (co-opted for anti-virals)	Consultant Respiratory Physician, West Hertfordshire Hospitals NHS Trust	Non-financial professional and personal	Relevant academic publication: Greenhalgh, Trisha; Knight, Matthew (2020) 'Long COVID: a primer for family physicians' American Family Physician, 102, 12: pp. 716-717	2020	Declare and participate. Interest is non-specific to anti-virals under consideration
Dr Matthew Knight (co-opted for anti-virals)	Consultant Respiratory Physician, West Hertfordshire Hospitals NHS Trust	Non-financial professional and personal	Relevant academic publication: Shah, S; Gvozdanovic, A; Knight, M; Gagnon, J (2020) 'PMD35 Remote Patient Monitoring in ACUTE Medical Conditions; CAN Digital Health Solutions Reduce Clinician Workload and Ease the Pressure on Healthcare Providers during the COVID Crisis?' Value in Health, 23: S582	2020	Declare and participate. Interest is non-specific to anti-virals under consideration
Dr Matthew Knight (co-opted for anti-virals)	Consultant Respiratory Physician, West Hertfordshire Hospitals NHS Non-financial professional and personal Trust	Non-financial professional and personal	Relevant academic publication: Knight, Matthew; Yunger, Patricia; Wu, Zhe; Barlow, Andrew (2019) 'The Rocket Pleural Vent in Pneumothorax' European Respiratory Society	2019	Declare and participate. Interest is non-specific to anti-virals under consideration
Dr Matthew Knight (co-opted for anti-virals)	Consultant Respiratory Physician, West Hertfordshire Hospitals NHS Trust	Non-financial professional and personal	Relevant academic publication: Roy, Kay; Groom, Katherine; Knight, Matthew (2018) 'Point of care respiratory viral testing (POCT): A novel service to target appropriate antimicrobial prescription and improve antibiotic stewardship' European Respiratory Society	2018	Declare and participate. Interest is non-specific to anti-virals under consideration

Name	Job title and organisation	Type of interest	Description of interest	Relevant dates	Comments
Dr Matthew Knight (co-opted for anti-virals)	Consultant Respiratory Physician, West Hertfordshire Hospitals NHS Trust	Non-financial professional and personal	Relevant academic publication: Roy, Kay; Kandil, Hala; Knight, Matthew; Thapa, Mohan; Groom, Katherine (2018) 'Respiratory viral point of care testing (POCT) allows improved infection control and bed management during an influenza outbreak' European Respiratory Society	2018	Declare and participate. Interest is non-specific to anti-virals under consideration
Dr Matthew Knight (co-opted for anti-virals)	Consultant Respiratory Physician, West Hertfordshire Hospitals NHS Trust	Non-financial professional and personal	Relevant academic publication: Roy, K; Groom, K; Read, N; Cucciniello, C; Knight, M (2018) 'S99 Point of care testing for respiratory viruses (RPOCT): a novel service to facilitate appropriate discharge and infection control measures and improve antimicrobial stewardship' BMJ Publishing Group Ltd	2018	Declare and participate. Interest is non-specific to anti-virals under consideration
Dr Matthew Knight (co-opted for anti-virals)	Consultant Respiratory Physician, West Hertfordshire Hospitals NHS Trust	Non-financial professional and personal	Relevant academic publication: Knight, Matthew; Yazbeck, Leda; Hanger, Sofia; Butters, Oliver; Creer, Dean (2014) 'The role of a pleural service in optimising pleural disease management' European Respiratory Journal, 44, 58	2014	Declare and participate. Interest is non-specific to anti-virals under consideration
Dr Matthew Knight (co-opted for anti-virals)	Consultant Respiratory Physician, West Hertfordshire Hospitals NHS Trust	Non-financial professional and personal	Relevant academic publication: Knight, MJ; Hyatt, PJ (2006) 'The effect of bisphosphonates on calcium and parathyroid hormone levels in patients with primary hyperparathyroidism over 2 years' 197 th Meeting of the Society for Endocrinology, 12	2006	Declare and participate. Interest is non-specific to anti-virals under consideration
Dr Matthew Knight (co-opted for anti-virals)	Consultant Respiratory Physician, West Hertfordshire Hospitals NHS Trust	Non-financial professional and personal	Relevant academic publication: Javid, Babak; Knight, Matthew; Inada-Kim, Matt. '¿Cuál es la eficacia y seguridad de las pruebas rápidas de ejercicio para la desaturación por esfuerzo en covid-19?' (What is the efficacy and safety of rapid exercise tests for exertional desaturation in COVID-19?)	2020	Declare and participate. Interest is non-specific to anti-virals under consideration
Craig Morris (co-opted for respiratory support and awake prone positioning)	Consultant in Anaesthetics and Intensive Care, Derby & Burton Hospitals Foundation Trust	N/A	None	August 2021	Declare and participate
Dr Marlies Osterman (co-opted for respiratory support)	Consultant in Nephrology and Critical Care, Guys and St	Non-Financial professional and personal	Elected member of the council of the Intensive Care Society	January 2020 - present	Declare and participate

Name	Job title and organisation	Type of interest	Description of interest	Relevant dates	Comments
and awake prone positioning)	Thomas NHS Foundation Trust				Interest is non-specific for respiratory update
Dr Marlies Osterman (co-opted for respiratory support and awake prone positioning)	Consultant in Nephrology and Critical Care, Guys and St Thomas NHS Foundation Trust	Non-Financial professional and personal	Director of Research (Intensive Care Society)	January 2021 – present	Declare and participate Interest is non-specific for respiratory update
Dr Marlies Osterman (co-opted for respiratory support and awake prone positioning)	Consultant in Nephrology and Critical Care, Guys and St Thomas NHS Foundation Trust	Non-Financial professional and personal	Member of AKI!Now, a working group of the American Society of Nephrology to raise awareness about acute kidney injury	January 2021 – present	Declare and participate Interest is non-specific for respiratory update
Dr Marie Scully (Co-opted for heparins/VTE)	Consultant Haematologist, University College London Hospital	Direct, financial	Advisory board and speakers' fees for Sanofi, Takeda and Octa pharma, the advice and presentations were in specific to Thrombotic Thrombocytopenic Purpura. I have advised Novartis board exclusively on Idiopathic thrombocytopenic Purpura and eltrombopag. None of these interests have been in relation to COVID-19, vaccine related or VITT	January 2018 – ongoing	Declare and participate. The interest is not specific for heparins/VTE. Open declaration is sufficient mitigation
Dr Marie Scully (Co-opted for heparins/VTE)	Consultant Haematologist, University College London Hospital	Direct, financial	Grants from Shire - not relevant to COVID-19 and VTE/Heparins.	2018 - 2021	Declare and participate Interest is non-specific for heparins/VTE
Dr Marie Scully (Co-opted for heparins/VTE)	Consultant Haematologist, University College London Hospital	Direct, financial	Grant from Novartis - not relevant to COVID-19 and VTE/Heparins.	2020 - 2022	Declare and participate Interest is non-specific for heparins/VTE
Dr Marie Scully (Co-opted for heparins/VTE)	Consultant Haematologist, University College London Hospital	Non-financial professional and personal	Chair of Clinical guide for the prevention, detection and management of thromboembolic disease in patients with COVID-19 : ICU society, ICM, Association of anaesthetics, RCoA, RCP	April 2020 – 27 th May 2020	Declare and participate Interest is non-specific for heparins/VTE

Name	Job title and organisation	Type of interest	Description of interest	Relevant dates	Comments
Dr Marie Scully (Co-opted for heparins/VTE)	Consultant Haematologist, University College London Hospital	Non-financial professional and personal	Ttp-caplacuzimab – Hercules - not relevant to COVID-19 and VTE/Heparins.	Ongoing	Declare and participate Interest is non-specific for heparins/VTE
Dr Marie Scully (Co-opted for heparins/VTE)	Consultant Haematologist, University College London Hospital	Non-financial professional and personal	HUS-revoluzumab - alx1210 - not relevant to COVID-19 and VTE/Heparins.	February 2020 – March 2020	Declare and participate Interest is non-specific for heparins/VTE
Dr Marie Scully (Co-opted for heparins/VTE)	Consultant Haematologist, University College London Hospital	Non-financial professional and personal	Phase II and III studies on recombinant ADAMTS 13 - not relevant to COVID-19 and VTE/Heparins.	Ongoing	Declare and participate Interest is non-specific for heparins/VTE
Anand Shah (co-opted for COVID-19 associated pulmonary aspergillosis)	Consultant Respiratory Physician, Royal Brompton and Harefield NHS Foundation Trust	Direct financial	Gilead Sciences - Speaker fees for presentation at educational conference GAIN2021. Presentation was on non-aspergillus mould infection in chronic lung disease.	2020 - 2021	Declare and participate Interest is non-specific for CAPA
Anand Shah (co-opted for COVID-19 associated pulmonary aspergillosis)	Consultant Respiratory Physician, Royal Brompton and Harefield NHS Foundation Trust	Direct financial	Pfizer - Research grant for investigator led research proposal unrelated to current topic A broader observational retrospective epidemiological electronic health record study analysing burden of fungal disease in the UK over a 10-year period ranging from allergy, chronic disease through to invasive fungal disease across all disease groups and settings.	April 2021 – October 2023	Declare and participate Interest is non-specific, out of scope for CAPA
John Skull (co-opted for respiratory support)	Senior Nurse - Patient Emergency Response and Resuscitation Team, University College London Hospitals NHS Foundation Trust	N/A	None	August 2021	Declare and participate
Andrew Slack (co-opted for awake prone positioning and non-invasive)	Consultant Intensivist, Guy's and St Thomas'	N/A	None	February 2022	Declare and participate

Name	Job title and organisation	Type of interest	Description of interest	Relevant dates	Comments
respiratory support update)	NHS Foundation Trust				
Amanda Thomas (co-opted for awake prone positioning and non-invasive respiratory support update)	Clinical Specialist Physiotherapist, Critical Care Outreach - Barts Health NHS Trust	Non-financial professional and personal	Published paper on related topic area Sayer, K., Grady, A., Church, D and Thomas, A.J. (2021) Characteristics and therapy needs of COVID-19 survivors between critical care and acute hospital discharge: A single centre observational cohort study. Physiotherapy UK Conference (Poster presentation)	January 2021 – ongoing	Declare and participate Interest is non-specific for awake prone positioning and non-invasive respiratory support update.
Amanda Thomas (co-opted for awake prone positioning and non-invasive respiratory support update)	Clinical Specialist Physiotherapist, Critical Care Outreach - Barts Health NHS Trust	Non-financial professional and personal	Published paper on related topic area Rich, J., Coman, M., Sharkey, A., Church, D., Pawson, J and Thomas, A.J. (2021) A single center observational study of the incidence, frequency and timing of Physiotherapy intervention during the COVID-19 pandemic. World Congress of Physical Therapy, 2021 Online conference (Poster presentation)	January 2021 – ongoing	Declare and participate Interest is non-specific for awake prone positioning and non-invasive respiratory support update.
Amanda Thomas (co-opted for awake prone positioning and non-invasive respiratory support update)	Clinical Specialist Physiotherapist, Critical Care Outreach - Barts Health NHS Trust	Non-financial professional and personal	Published paper on related topic area Mansell, S.K., Exall, T., Greenham, L., Page, R and Thomas, A.J. (2020) A multi-center observational study of Tracheostomy outcomes during the first surge of the COVID-19 pandemic. British Thoracic Society Winter Meeting, Dec 2020, (Poster presentation)	January 2021 – ongoing	Declare and participate Interest is non-specific for awake prone positioning and non-invasive respiratory support update.
Amanda Thomas (co-opted for awake prone positioning and non-invasive respiratory support update)	Clinical Specialist Physiotherapist, Critical Care Outreach - Barts Health NHS Trust	Non-financial professional and personal	Published paper on related topic area Causon, J., Cary, R., Thomas, A.J. (2021) Decannulation failure following Tracheostomy for COVID-19 - A single case report. Journal of Clinical Case Reports and Studies, 2021, 3(5); DOI: 10.31579/2690-8808/082	January 2021 – ongoing	Declare and participate Interest is non-specific for awake prone positioning and non-invasive respiratory support update.
Amanda Thomas (co-opted for awake prone positioning and non-invasive respiratory support update)	Clinical Specialist Physiotherapist, Critical Care Outreach - Barts Health NHS Trust	Non-financial professional and personal	Published paper on related topic area Rich, J., Coman, M., Sharkey, A., Church, D., Pawson, J and Thomas, A.J. (2021) A single center observational study of the incidence, frequency and timing of Physiotherapy intervention during the COVID-19 pandemic. Journal of the Intensive Care Society, Feb, 2021: DOI: 10.1177/1751143721991060	January 2021 – ongoing	Declare and participate Interest is non-specific for awake prone positioning and non-invasive respiratory support update.

Name	Job title and organisation	Type of interest	Description of interest	Relevant dates	Comments
Dr Caroline O’Keeffe (Co-opted for anti-virals)	Medical Director, North Hampshire Urgent Care and Clinical Lead for COVID and Virtual Wards – North and Mid Hampshire	Non-financial professional and personal	Clinical Lead for North and Mid Hampshire CO@h service (COVID Oximetry at Home) and COVID and virtual wards.	2 nd June 2021 Ongoing	Declare and participate Interest is non-specific
Dr Caroline O’Keeffe (Co-opted for anti-virals)	Medical Director, North Hampshire Urgent Care and Clinical Lead for COVID and Virtual Wards – North and Mid Hampshire	Non-financial professional and personal	Co-author for preprint study: COVID Oximetry @home: evaluation of patient outcomes https://www.medrxiv.org/content/10.1101/2021.05.29.21257899v2	June 2021 - ongoing	Declare and participate Interest is non-specific to anti-virals under consideration Declaration is sufficient mitigation
Dr Brijesh Patel (co-opted for CAPA)	Clinical Senior Lecturer and Consultant in Cardiothoracic, Imperial College London	Direct-financial	Critical Care Digital Advisory Board on Invasive Fungal Disease, an educational event by Gilead with an aim to understand current practice and knowledge gaps in diagnosis and treatment of invasive fungal disease within the critical care setting. I received a one-off payment for this role.	December 2021 - January 2022	Declare and participate but partial exclusion for future updates. Direct-financial interest specific to the manufacturer of an intervention under consideration which arose following the panel meetings and drafting of recommendations in 2021. Can participate in discussion of future evidence to provide expertise, exclusion of drafting associated recommendations.
Brijesh Patel (co-opted for COVID-19 associated pulmonary aspergillosis)	Clinical Senior Lecturer and Consultant in Cardiothoracic Critical Care,	Non-financial professional and personal	Grants from European Commission and Imperial College London Covid-19 Fund to phenotype Severe Acute Respiratory Failure and COVID-19. Grants originally for non-Covid severe respiratory failure, later re-purposed for Covid-19.	April 2019 - ongoing	Declare and participate Interest is non-specific

Name	Job title and organisation	Type of interest	Description of interest	Relevant dates	Comments
	Imperial College London				
Brijesh Patel (co-opted for COVID-19 associated pulmonary aspergillosis)	Clinical Senior Lecturer and Consultant in Cardiothoracic Critical Care, Imperial College London	Non-financial professional and personal	Grants for student PhD fellowships from HCA UK	April 2020 - ongoing	Declare and participate Interest is non-specific
Brijesh Patel (co-opted for COVID-19 associated pulmonary aspergillosis)	Clinical Senior Lecturer and Consultant in Cardiothoracic Critical Care, Imperial College London	Non-financial professional and personal	Grants from Royal Brompton and Harefield Charity for PhD studentship	March 2018 – ongoing	Declare and participate Interest is non-specific
Brijesh Patel (co-opted for COVID-19 associated pulmonary aspergillosis)	Clinical Senior Lecturer and Consultant in Cardiothoracic Critical Care, Imperial College London	Non-financial professional and personal	Research grant for investigator led study on mechanical ventilation from Mermaid Care A/C	March 2019 – ongoing	Declare and participate Interest is non-specific to CAPA
Brijesh Patel (co-opted for COVID-19 associated pulmonary aspergillosis)	Clinical Senior Lecturer and Consultant in Cardiothoracic Critical Care, Imperial College London	Non-financial professional and personal	Data Safety Monitoring Board member for Locyte trial sponsored by Faraday Pharmaceuticals, examining FDY-5301 which is an elemental reducing agent being developed by the company for the prevention and treatment of ICU-acquired weakness (ICUAW) and other muscle related conditions.	April 2018 – ongoing	Declare and participate Interest is non-specific to CAPA
Brijesh Patel (co-opted for COVID-19 associated pulmonary aspergillosis)	Clinical Senior Lecturer and Consultant in Cardiothoracic Critical Care, Imperial College London	Direct financial	Managing Director with 100% share - Critical Care Innovations Ltd - Consultancy and private practice. Approximately 10% of work (time spent) alongside NHS work. Does not treat patients with CAPA.	August 2021 - ongoing	Declare and participate Interest is non-specific to CAPA
Louisa Weighill (co-opted for	Clinical – Specialist	N/A	None	August 2021	Declare and participate

Name	Job title and organisation	Type of interest	Description of interest	Relevant dates	Comments
respiratory support)	Physiotherapist, UCLH				
Debbie Van Der Velden (co-opted for respiratory support and awake prone positioning)	Clinical Nurse Fellow for Improvement and Innovation, Chelsea and Westminster NHS Foundation Trust	N/A	None	August 2021	Declare and participate